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INTRODUCTION 
 
 
1) Human African trypanosomiasis 
 
The Kinetoplastida are a protozoan class belonging to the Excavata supergroup, 
encompassing numerous medically and agriculturally important pathogens, as well as free-
living representatives that have huge ecological impact.4.   
 
Within the kinetoplastida, the order Trypanosomatida contains many pathogens, including 
Trypanosoma brucei, T. cruzi and Leishmania spp., the causative agents of African 
trypanosomiasis, Chagas‘ disease and leishmaniasis respectively. These parasites have 
evolved diverse immune evasion strategies; while Leishmania spp. and T. cruzi exploit 
intracellular lifestyles by invasion of host cells, T. brucei persists within the host 
bloodstream and lymphatic system, and is therefore continually exposed to both innate and 
adaptive immune mechanisms. The surface of mammalian infective T. brucei is dominated 
by approximately 2 x 10
7
 molecules of a single GPI-anchored variant surface glycoprotein 
(VSG), shielding invariant surface antigens from antibody recognition4.   
 
Trypanosoma brucei brucei causes the veterinary disease Nagana, but it is unable to 
establish infections in humans. Human resistance to T. brucei brucei infection is due to the 
presence of  a trypanolytic component of human serum, which provides innate immunity 
against infection. This component is a minor subfraction of high-density lipoproteins 
(HDLs) called the trypanosome lytic factor 1 (TLF-1). This toxic class of HDLs is 
internalized in T. brucei brucei via receptor-mediated endocytosis and is ultimately 
targeted to the lysosome, where it initiates low-pH-dependent killing. However, T. b. 
rhodesiense and T. b. gambiense, managed to escape this immunity system, enabling them 
to grow in humans where they cause sleeping sickness, as Human African 
Trypanosomiasis (HAT) is called.5          
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The mechanism of resistance to TLF-1 remains to be fully elucidated; however, it is well 
established that the resistance phenotype of T. brucei gambiense (chronic form of the 
disease in West Africa- Congo) and T. brucei rhodesiense (acute form in Est Africa- 
Zimbabwe, Tanzania, Zambia, Angola (Figure 1) is due to the expression of the serum 
resistance associated (SRA) protein (a member of the VSG gene family). 1.   
 
 
2) Life Cycle of Trypanosoma brucei.  Early and Late Symptoms 
 
Both trypanosomes are morphologically identical and are transmitted to human hosts by 
bites of infected tsetse flies (Glossina palpalis transmits T. brucei gambiense and Glossina 
morsitans transmits T. brucei rhodesiense), which are found only in Africa. 2. 
 
Life cycle of the parasites starts when the trypanosomes are ingested during a blood meal 
by the tsetse fly from a human reservoir in West African trypanosomiasis or an animal 
reservoir in the East African form. The trypanosomes multiply over a period of 2-3 weeks 
in the fly midgut; then, the trypanosomes migrate to the salivary gland, where they develop 
into epimastigotes. The metacyclic trypomastigotes infect humans, following a fly bite, 
which occasionally causes a skin canker at the site 54. 
In the first stage, the trypanosomes multiply in subcutaneous tissues, blood and lymph. 
This is known as a haemolymphatic phase, which entails bouts of fever, headaches, joint 
pains and itching. 
 
In the second stage the parasites cross the blood-brain barrier to infect the central nervous 
system. This is known as the neurological phase. In general this is when more obvious 
signs and symptoms of the disease appear: changes of behaviour, confusion, sensory 
disturbances and poor coordination. Disturbance of the sleep cycle, which gives the disease 
its name, is an important feature of the second stage of the disease. Without treatment, 
sleeping sickness is considered fatal. The  first stage of T. brucei gambiense sleeping 
sickness is long and relatively asymptomatic 55. 
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3) Epidemiological studies 
 
Epidemiological studies  indicate that this disease threatens millions of people in 36 
countries in sub-Saharan Africa. Many of the affected populations live in remote areas with 
limited access to adequate health services, which hampers the surveillance and therefore 
the diagnosis and treatment of cases. In addition, displacement of populations, war and 
poverty are important factors leading to increased transmission and this alters the 
distribution of the disease due to weakened or non-existent health systems. 8 
 
In 2009, after continued control efforts, the number of cases reported has dropped below 
10 000  for the first time in 50 years. This trend has been maintained in 2010 with 7139 
new cases reported (WHO). Despite these efforts, the problematic of internal conflicts by 
armed groups has impaired the work of sanitary control of active outbreaks of disease as 
well as promoted the mobilization of citizens to areas where they are more exposed to the 
vector and access to health centre  to treat the disease is less or naught. 
 
Additionally cases of African trypanosomiasis have been reported in recent years in 
travellers coming from various parts of Africa, particularly from the natural parks of 
Tanzania 6;7  
 
This means that although African trypanosomiasis is endemic in an area of Africa, there is 
a high risk factor for travellers. 
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          Figure 1: WHO Report on Global Surveillance of Epidemic -prone Infectious  
           Diseases African trypanosomiasis 
 
 
4) Drugs and target  
 
Currently development of effective vaccines against these parasites remains an unrealized 
goal and clinical management is based on chemotherapeutics. Cost, toxicity and resistance 
problems of conventional drugs result in an urgent need to identify and develop new 
therapeutic alternatives. Traditionally, neglected tropical diseases have not been the focus 
of robust efforts to identify new drugs due to lack of a profitable market and effective 
strategies to implement control programmes 9.   
 
The global effort to control the infection is based on a combination strategy of vector 
control and drug treatment of infected patients. Currently there is no drug that is effective 
against both stages of the disease or both subspecies, and all therapies require parenteral 
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administration (Table 1). Early-stage disease is treated with pentamidine (T. b. gambiense) 
or suramin (T. b. rhodesiense) 9], but both compounds show some toxicity. 
Suramin has been reported to inhibit a number of glycolytic enzymes 10, including a 
recent report that it inhibits pyruvate kinase by binding the ATP site as shown by X-ray 
structure analysis 11.        
Treatment of late-stage disease is more problematic. Historically the highly toxic arsenical 
compound melarsoprol was used to treat both subspecies of the disease, causing 5–10% 
fatality in treated patients. However in 2009 a new nifurtimox/eflornithine combination 
therapy (NECT) was advanced for the treatment of late-stage T. b. gambiense after 
showing equivalent to better efficacy than eflornithine (DFMO) alone in clinical trials.  
NECT has not yet been tested against T. b. rhodesiense, and despite improvements over 
eflornithine alone, administration still requires 7 days of twice daily i.v. infusions of 
eflornithine along with oral nifurtimox administration. 9.   
 
 
Table 1: HAT drugs in clinical use. 
 
The organization Drugs for Neglected Diseases Initiative (DNDi) is emphasizing 
development of new compounds, such as oxaborole SCYX-7158 and fexinidazole for the 
treatment of both early and late-stage disease and they are currently undergoing clinical 
trials  9.   
 
Eflornithine target has been shown to be ornithine decarboxylase, an essential enzyme in 
the biosynthesis of polyamines 12. Regarding nifurtimox, there is good evidence that 
activation by a type I nitroreductase leading to production of intracellular free radicals, is 
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key to its efficacy 13;16. Analogues of pentamidine have been shown to collapse the 
mitochondrial membrane potential but the protein targets that mediate these effects are 
unknown 14. Recent efforts to utilize genome-wide RNAi approaches have led to the 
identification of genes involved in suramin uptake, and to the identification of several other 
lysosomal proteins that contribute to its action 15. However, for pentamidine, suramin 
and melarsoprol, a number of genes were identified that modulate their function, 
suggesting that clear identification of their molecular targets will not be straightforward  
9.         
 
Others proteins such as trypanothione reductase, which are unique for trypanosomes, have 
been proposed as ideal target [9]. However also other enzymes, which are present both in 
parasites and in the guests, may be effective targets, if they have structural characteristics 
that may be subject to selective inhibitors, such the case of ornithine decarboxylase. This 
was clearly demonstrated also in the case of the enzyme of glycolysis glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). Differences in the binding site of the coenzyme 
(NAD+) were identified using a comparative analysis by X-ray crystallography [10]. 
Structures adenosine-based, as analogues of the co-factor, have been shown to selectively 
inhibit the enzymes of trypanosome and also to kill both T. brucei and T. cruzi. [19].  
 
The  bloodstream-form of T. brucei has the blood glucose as the sole source of nutrition. 
For this reason, the glycolysis that is responsible for substrate-level ATP production in the 
cell, was considered a good target for the development of new drugs. The absence of 
glucose or incubation of the parasite with inhibitors of certain glycolytic enzymes, leads to 
a rapid lysis and death of the parasite present in the bloodstream of the host. Also 
demonstrations based on mathematical models and experiments of gene knock-out 
revealed that glycolysis is essential and validated this pathway as drug target. [18, 52] 
. 
Glycosomes are a specialized form of peroxisomes (microbodies) present in unicellular 
eukaryotes that belong to the Kinetoplastea order, such as Trypanosoma and Leishmania 
species. The organelles harbour most enzymes of the glycolytic pathway 52. Some drug 
targets may be found in the glycosomes compartments, and in the metabolism of lipids and 
of purines too [6]. 
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The pentose phosphate pathway also plays a crucial role in the metabolism of the parasite 
and in the host-parasite relationship, since its main function is the production of NADPH, 
which is necessary for the defense against oxidative stress and for different reductive 
biosynthetic reactions. (Figure 2). 
 
 
           Figure 2: Pentose Phosphate Pathway. 6PGDH is the third enzyme of 
      the Pentose Phosphate Pathway (Gupta S et al 2011) 
 
 
 
The decrease of the availability of this reduced coenzyme increases susceptibility to 
oxidative stress and hampers the reductive biosyntheses of the parasite. [20]. 
6-phosphogluconate dehydrogenase (6PGDH) is the third enzyme of the pentose phosphate 
pathway, it catalyzes the oxidative decarboxylation of 6-phosphogluconate (6PG) to 
ribulose-5-phosphate (RU5P), with redox reaction preceding decarboxylation , via 3-keto 
6PG and a probable 1, 2-enediol as intermediates (Figure 3) 
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              Figure 3: reaction catalyzed by 6-PGDH and the two main amino acid  
              residues involved 
 
 
The inhibition of 6PGDH causes an accumulation of 6PG in the cell, which acts as an 
inhibitor of 6-phosphoglucose isomerase, the enzyme that converts glucose-6-phosphate to 
fructose-6-phosphate during glycolysis. The accumulation of glucose-6-phosphate in the 
cell addresses this to enter the pentose phosphate pathway by triggering a positive 
feedback loop that feeds on itself with fatal consequences for the parasite. [21].  
Enzyme inhibition studies have shown that there are strong inhibitors against 6PGDH, 
which show some selectivity versus the parasite enzyme compared the mammalian one. T. 
brucei 6PGDH shows only a 33% amino acid identity with the mammalian 6PGDH even if 
their structures have a similar overall fold and many residues nearest neighbours to the 
substrate are conserved 22     
 
Three reviews have dealt with T. brucei 6PGDH inhibitors as lead compounds for new 
drugs against African trypanosomes [21,23,53]. Inhibitors have been found, which mimic 
the transition-state and high-energy intermediates of the enzymatic reaction of 6PGDH 
[24]. Hydrophobic analogues of these also revealed some anti-parasite activity [25]. A 
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number of phosphorylated carboxylic acids derived from aldose sugars were tested against 
6PGDH, two particularly notable inhibitors were identified. Both 4-phospho-D-erythronate 
(4PE) and 5-phospho-D-ribonate (5PR) (Fig. 4, compounds 1 and 2) were competitive with 
respect to substrate, with Ki values for the T. brucei 6PGDH equal to 130 and 950 nM, 
respectively.  
 
 
 
Figure 4: Structures of some substrate analogues (Ac=Acetyl group). . 4-phospho-D-erythronate 
(compounds 1);  5-phospho-D-ribonate (compounds 2) ; 4-phospho-D-erythronohydroxamate  (compound 3), 
4-phospho-D-erythronamide  (compound 4) and two protected analogues of 4-phospho-D-
erythronohydroxamate  (compounds 5  and 6)  
 
 
Their selectivities for the T. brucei 6PGDH over the sheep liver one (ratio Ki sheep/ Ki T. 
brucei) were measured at 83-fold and 70-fold respectively. Ki values for both are under the 
Km for 6PG (= 3.5 μM), indicating that they mimic high energy reaction intermediates ( 
Figure 3) rather than the substrate per se [21,26, 19]. 
 
 
Another potent and selective T. brucei 6PGDH inhibitor is 4-phospho-D-
erythronohydroxamate (Figure 4, compound 3), synthesized specifically to mimic the high-
energy intermediates produced following the second (decarboxylation) step of the 
catalyzed reaction, shown in Figure 3 . This hydroxamate, with a Ki = 10 nM and 
selectivity of 254-fold for the parasite enzyme over the sheep liver enzyme, is the 
compound with the highest affinity for the T. brucei 6PGDH reported to date and it also 
shows the highest selectivity for the parasite over the sheep liver enzyme [24]. In Table 2, 
inhibition constants versus 6PG (Ki) at pH 7.5 (which is the enzyme optimum pH) for all 
T. brucei 6PGDH inhibitors, which are shown in the figures included in this text, are 
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reported, together with selectivity values over the sheep liver enzyme (ratio sheep liver 
6PGDH Ki / T. brucei 6PGDH Ki). 
 
 
 
            Table 2: 6PGDH inhibition constants of compounds in figure 4.. 4-phospho-D-erythronate        
 (compounds 1);  5-phospho-D- (compounds 2) ; 4-phospho-Derythronohydroxamate(compound 3) ; 
 4-phospho-D-erythronamide  (compound 4) and two protected analogues of 4-phospho-D-
 erythronohydroxamate  (compounds 5  and 6) 
 
 
 
Genetic studies and RNA interference, which leads to the selective suppression of the 
expression of a gene, are today highly used, also for their extreme speed, to verify the 
effect of inhibition of an enzyme in the parasite [21]. These studies have indicated that in 
T. brucei 6PGDH can be a drug target since expression of the gene encoding 6PGDH has 
been shown essential for growth of T. brucei bloodstream form. 
 
 
 
5) Structure of 6-phosphogluconate dehydrogenase 
 
5.a) Primary structure 
The comparative study of the amino acid sequence, using alignment, has  revealed  a 33% 
identity between the amino acid sequence of T.  brucei 6PGDH and mammalian enzyme 
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43 while identity is somewhat higher (37.3%) both with the chloroplast and the cytosolic 
6PGDH from spinach [42]. 
 
This may reflect the evolutionary history of the kinetoplastids, the phylogenetic order to 
which trypanosomes belong, which have been proposed to have derived from an ancestor 
common with the primitive plants Euglenoid algae [40].  
 
Furthermore the closer relationship between the genes of Trypanosoma and those of 
cyanobacteria and  plastids as well as algal and plant genes rather than with those of other 
eukaryotic lineages can be explained by the fact that some ancestors of trypanosomes 
housed in endosymbiont prokaryotes from which a number of genes was then acquired by 
the nucleus of the trypanosome. Some enzymes of  the glycolytic pathway and other 
pathways seem very close to those found in cyanobacteria and plastids [21]. 
 
The sequence of 6PGDH from different species, have been aligned using the programs 
MultAlin [36] e ESPript [37] to show the conserved amino-acids among species. Of the 
482 amino-acids that belong to one subunit, 88 are conserved in all species (Figure 5) [46]. 
 
 
 
5.b)  The 3-dimensional structure  
The 3-dimensional structure of the T. brucei 6-phosphogluconate dehydrogenase has been 
solved at 2.8 Å resolution [22]. The sheep liver enzyme, which has 97% sequence identity 
to the human enzyme, has been described at 2 Å [47] resolution and enzyme-coenzyme 
and enzyme-substrate complexes have been reported at 2.3 Å -2.5 Å resolution [39]. The 
structures of  Lactococcus lactis 6PGDH in ternary complex with NADP and the product 
Ru5P or the inhibitor 4-phospho-D-erythronohydroxamic acid (PEX) were also reported 
[48].   
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            Figure 5. Multiple alignment of 6PGDH from several species. 
 
5.c)  The T.brucei monomer 
Each  monomeric subunit weighs 52 kDa and it is formed by 482 amino acid residues. The 
T. brucei monomer is comprised of three domains or regions (Figure 6): 
 
An N-terminal domain or coenzyme binding (residues 1-178), characterized by a 
Rossmann fold typical for binding to dinucleotides (residues 1-130, sheets from βA to βF 
alternating with intervening helices) and a unit α-β-α (residues 132 to 161, αf-βG-αg) with 
a section βG antiparallel to the first six strands. The coenzyme binding site is at the 
carboxyl ends of the strands of the parallel sheet, with the two ribose moieties and the bis-
phosphate straddling the sheet. The dinucleotide binding fingerprint, at the tight turn 
following A, is GxGxxG in the T. brucei enzyme while in the ovine enzyme it is 
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GxAxxG as in almost all known 6PGDHs. As the two subunits of the T. brucei dimer were 
not crystallographically equivalent, slightly different conformations of two loops in the 
coenzyme domain could be seen [39]. 
 
 
 
                          Figure 6: Monomer of the T. brucei 6PGDH. 
 
 
 
Central helical domain "all helix" (residues 179-441) that includes most of the protein, 
formed only by alpha helices; it forms a part of the interface of the dimer and the binding 
site to the substrate. 
 
C-terminal "tail" (442-478), of small dimensions which penetrates the central domain of 
the second subunit, thus completing the binding site to the substrate. (Figure 6). 
 
 
5.d) Coenzyme binding-site 
The coenzyme binding domain of 6PGDH has 70 residues identical in the sheep and T. 
brucei enzymes (Figure 7), 35 of which are totally conserved.  
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         Figure 7. Coenzyme binding site 
 
In the oxidized coenzyme binding site, there are 17 residues within 4 Å from the oxidised 
coenzyme analogue, nicotinamide-8-bromo-adenine dinucleotide phosphate (Nbr
8
ADP+) 6 
of which are totally conserved and 12 are identical in T. brucei and sheep. 
 
The Km for NADP+ for T. brucei 6PGDH is 1 µM while that for sheep enzyme is several 
times higher ranging from 5.7-8.9 µM depending on pH and ionic strength [49]. Sequence 
differences at the coenzyme binding site may affect the affinity for NADP+ between 
species. 
 
Thus, although most of the binding site is highly conserved, however, some small 
difference exists. Between these, the most important are the transformation of Ala 11 
(sheep) in Gly 10 (T. brucei), of Lys 75 (sheep) in Gln 77 (T. brucei); and Phe 83 (sheep) 
in Thr 85 (T. brucei) [21]. The mean main-chain movement for the 17 residues of the sheep 
enzyme on binding the analogue is 0.31 Å; only Lys 75s moves significantly (0.77 Å). 
 
Among the hydrogen bond interactions of the sheep enzyme with oxidised coenzyme, that 
of the 2‘-phosphate and adenine ribose to triplet Asn 32s, Arg 33s, Thr 34s directly 
following βB (Asn 31, Arg 32, Thr 33 in T. brucei) is predominant. The additional 
hydrogen bonds are to the nicotinamide amide function from a conserved methionine of 
the fingerprint (Met 13s) and from a glutamate of αf (Glu 131s) conserved in 68 of 70 
species. All residues with side-chain hydrogen bonds are conserved between sheep and T. 
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brucei, though it should be noted that, in two other species, a tyrosine replaces the arginine 
32, (33s), which interacts with the 2‘- phosphate. The most important changes in sequence 
between the sheep and T. brucei enzymes, which may affect binding are Ala 11s to Gly 10, 
Lys75s to Gln 77 and Phe 83s to Thr 85. The Cβ of Ala 11s in sheep 6PGDH protrudes 
into the bis-phosphate binding site. This residue corresponds to the central glycine of the 
generic fingerprint; the very small number of direct interactions of the bis-phosphate to the 
protein is almost certainly a consequence of this alanine. The substitution of glycine for 
alanine in the T. brucei enzyme should allow direct interactions between the enzyme and 
the NADP+ bis-phosphate and has a further consequence in that the highly conserved 
valine 11 (Val 12s) faces towards the putative nicotinamide site in T. brucei 6PGDH and 
away from it in the sheep enzyme. Val 11 would provide further Van der Waals contacts 
for the nicotinamide ring. The substitution of Gly 10 in the T. brucei enzyme would 
suggest a tighter binding of coenzyme as reflected in the higher affinity. 
 
All links between the 6PGDH side chains and the coenzyme are highly conserved in 
different species. 
 
Site-directed mutagenesis experiments in which the residue Arg 33 was mutated to tyrosine 
have revealed the importance of this residue in the binding of  2'-phosphate, which differs 
in the NADP compared to NAD [51].   
 
As the two subunits of the T. brucei dimer were not crystallographically equivalent, 
slightly different conformations of two loops in the coenzyme domain could be seen [39]. 
Crystallographic symmetry precludes such observations in the sheep liver enzyme. 
 
Structural studies on the ternary complex of the E. coli enzyme have shown that significant 
conformational changes of this site are required to open the binding pocket at the entrance 
or release of the coenzyme. Comparing the conformations of the catalytic sites of the two 
subunits of the enzyme, it seems that  while one is in the conformation "open", the other is 
in the conformation "closed", suggesting that the two subunits are working one at a time, 
consistent with the mechanism of "half -of-the-site reactivity "of the enzyme induced by 
the substrate [50]. Other conformational changes at the level of this domain occur 
following the reduction of the coenzyme. 
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5.e) The dimer interface 
Although the interface of the dimer is highly conserved, with 106 of the 134 residues 
involved, which in the enzyme of the parasite enzyme are structurally equivalent to those 
of sheep, only nine of them have a major role in the formation of the dimer. Three of these 
residues are part of the domain of the tail. In the enzyme of T. brucei the monomer-
monomer contact area is of 6210 Ǻ while in that of sheep is of 5488 Ǻ and the interface of 
the dimer in T. brucei presents a greater number of hydrophobic side chains (66 of 134 
compared to 49 of 115 of the sheep enzyme). 
 However, the most notable difference occurs at the point where the tail of a monomer 
crosses the other helping to form the binding site to the substrate. The tail of the enzyme of 
T. brucei, unlike  the sheep one, is full of charges, positive and negative: 13 out of 37 
residues are aspartate, glutamate, histidine, lysine and arginine in T. brucei, while only 7 of 
48 are charged in sheep. Of these 13 charged residues present in T. brucei, 5 form inter-
subunit salt bridges: two at the coenzyme binding domain and three in the helical domain. 
None of these salt bridges are conserved among different species. Instead two charged 
residues, Arg 453 and His 459, highly conserved, interact with sulphate ions firmly bound  
to the active site [22]. These differences at the level of the queues might be susceptible to 
drug-targeting [21]. 
 
 
         Figure 8. Dimer of the T. brucei 6PGDH. The two subunits are drawn in blue and in green. 
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5.f)  Substrate binding site 
The binding site to the substrate consists of 19 residues within a distance of 4 Å from the 
substrate 6PG: Asn 104 -102s (the sheep numbering is denoted by a lower case s), Ile 129 - 
Val 127s, Ser 130 - 128s, Gly 131 - 129s, Gly132- 130s, Lys185 - 183s, His 188-186s, Asn 
189 - 187s, Glu 192 - 190s, Tyr 193-191s, Ser 261- Gln 259s, Lys 262 -260s, Gly 263-
261s, Thr 264- 262s, Arg 289-287s, Ile 373- 366s, Arg 453-446s, Phe 456- 449s, His 459- 
452s (figure 9). 
 
Of these, 14 are conserved residues in all species studied: five residues from the domain of 
the coenzyme, eleven from the helical domain and three from the tail of the second 
subunit. Of particular importance is the triad S128 - H186 - N187, which turns out to have 
a multifunctional role in 6PGDH. Site-directed mutagenesis experiments have in fact 
indicated that these residues are involved in precatalytic conformational changes, helping 
to keep under control the balance between the open and closed conformation of the enzyme 
in the binding to 6PG (only S128 and H186) and to NAPDH (all three).  
 
The conserved  lysine (Lys 183s, Lys 185) predicted to be the base in the reaction is on h; 
the five residues in this helix, which interact with substrate, have moved less than 0.5 Å in 
the T. brucei 6PGDH compared to the sheep structure. 
 
 
         Figure 9: Substrate binding site. 
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Of particular importance is the Arg 446 (equivalent to Arg 453 of T. brucei) that binds the 
6-phosphate of the substrate. 
 
The N 1 of Arg 446s (Arg 453) is a ligand to the 6-phosphate of 6-phosphogluconate. In 
the sheep enzyme Arg 446s is oriented by a hydrogen bond from its N to the O1 of Gln 
443s (equivalent to Ser 450 in T. brucei), while Gln 443s N2 interacts with the carbonyl 
of Gly 258s (equivalent to Gly 260 in T. brucei).   
 
Residue 443s is therefore important in constraining the movement of Arg446s and defining 
the orientation of the phosphate of 6PG. In T. brucei 6PGDH, the hydroxyl of Ser 450 
hydrogen bonds to the main-chain carboxyl oxygen of Arg 258, but there is no interaction 
with Arg 453. Arg 458 interacts with the highly conserved Glu 133 (Glu 131s), which 
should have further implications for interaction with substrate since the carboxyl oxygens 
of 6PG  interact with residues of the F-f turn (130- 132, 128s- 130s). These residues 
have moved almost 1 Å from their position in the sheep enzyme; the movement is 
correlated with the differing inter-domain hinge angles.  
 
Despite the conservation of first neighbours to 6PG, these changes provide means by 
which the affinity for substrate and substrate analogues may vary between species, and 
suggest possible targets for substrate analogue and potential drug interaction. 
 
Additionally, in relation to the Arg 447 of L. lactis (equivalent to Arg 446 of sheep) site 
specific mutagenesis experiments of this residue mutated into Lys (with conservation of 
charge but size reduction), into Ala (with loss of charge), into Asp (with inversion of the 
charge) and Trp (with addition of an aromatic group) have confirmed that this residue 
plays a key role in the activity of the enzyme [52].  
 
Analysis of the structure revealed that, despite the structures of sheep and T. brucei 
6PGDHs are overall similar, alterations in specific residues involved in binding to the 
coenzyme, and structural differences that affect the way with which the enzyme binds the 
substrate, can be used for the development of selective inhibitors for the 6PGDH of T. 
brucei [21]. 
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6) Action mechanism of 6-phosphogluconate dehydrogenase 
 
 
6.a) The two key residues 
Two residues, one acting as an acid and the other as a base are postulated to assist all the 
three catalytic steps of the reaction: dehydrogenation, decarboxylation and keto-enol 
tautomerization. These residues, which in the T. brucei enzyme are Glu-192 and Lys-185, 
have been identified on the basis of crystallographic evidence and site-directed 
mutagenesis [27-28]. 
 
The lysine residue is thought to be protonated in the free enzyme and unprotonated in the 
enzyme-substrate complex, where it has to receive a proton from the 3-OH of 6PG as a 
hydride is transferred from C-3 of 6PG to NADP (Figure 3). 
 
The resulting 3-keto-6PG intermediate is then decarboxylated to form the enediol of 5-
phospho-ribulose. At this stage an acid, which is thought to be the same Lys-185, is 
required to donate a proton to the C-3 carbonyl group of the keto intermediate to facilitate 
decarboxylation. Both a base and an acid are needed in the tautomerization of the enediol 
intermediate to yield the ketone ribulose 5-phosphate product, with the acid (Glu-192) 
required to donate a proton to the C-1 of the enediol intermediate and the base (the same 
Lys-185) accepting a proton from its 2-hydroxyl (figure 3, and figure 10). At the end of the 
reaction, the protonation state of the two catalytic groups is the opposite to that at the 
beginning of the reaction; thus an intramolecular proton transfer is required for another 
cycle of enzyme activity. 
 
                Figure 10: T. brucei 6PGDH  active  site with the position of the  two      
                residues, discussed in  the  introduction. 
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6.b) Allosteric modulation by the substrate  
 
6.b.1 Asymmetry 
6PGDH is a homodimer, but, in many species, it shows functional and structural 
asymmetry [29- 30]. For instance, both the yeast and sheep liver enzyme bind covalently 
two molecules of periodate-oxidized NADP, but, in the presence of 6PG, a half-site 
reactivity is acquired with only one subunit binding the NADP analogue (Figure 11). The 
T. brucei 6PGDH also binds only one 3-amino-pyridine adenine dinucleotide phosphate 
(aPyADP) per dimer, in the presence of the substrate. NADP inhibition, at low 6PG 
concentrations, can also be explained by the fact that at low substrate concentration, 
equilibrium is shifted to the enzyme-(NADP)2 inactive form, incapable of binding the 
substrate, while at high substrate concentrations the equilibrium is shifted towards the 
enzyme-substrate active form [31]. Also 6PGDH from human erythrocytes shows a half-
of-the-sites reactivity, indeed it is able to bind two molecules of NADP, but only one of 
NADPH, and together with rat 6PGDH presents negative cooperativity for NADP. 
Furthermore, stopped-flow experiments with the sheep enzyme have indicated in the first 
turnover the formation of  only one NADPH molecule per enzyme dimer [32].  
 
 
  Figure 11:  Half of the site mechanism. In the presence of the substrate, modification of one of the 
 two NADP binding sites precludes the capability of binding NADP to the corresponding site 
 belonging to the other subunit. These experiments suggest that when one subunit is involved in the 
 ternary complex enzyme-6PG-NADP, the other subunit is unable to bind NADP and is thus inactive 
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6.b.2 Other 6PG-induced effects 
An other significant 6PG effect is the activation of the decarboxylation reaction of 3-keto 
2-deoxy 6PG, an analogue of the reaction intermediate 3-keto 6PG, consistent with 
asymmetry and better with an alternating site co-operativity model (Figure 12), since each 
subunit has only one substrate binding site. This model foresees that the two enzyme 
subunits have an alternating role in the oxidative decarboxylation: while one of the two 
equal subunits catalyses the redox reaction, the other subunit, with a different 
conformation, catalyses the decarboxylation and tautomerization reactions. Then the two 
subunits alternate their conformation and role. Both subunits are simultaneously active, 
participating in different steps of the reaction cycle and inverting the roles. According to 
this hypothesis while one of the two subunit binds the substrate, the other is involved in the 
decarboxylation of the intermediate 3-keto-6PG, which is accelerated by conformational 
changes induced by the binding of the substrate on both subunits. An alternative, less 
likely, hypothesis foresees the dimer with one permanently catalytic subunit and the other 
with only a regulatory role; in this case the turnover number would be lower [37]. 
 
The substrate binding site is made up of residues from both subunits, allowing the 
communication between the two active sites [38]. 
 
In the presence of either 6PG or phosphate or sulphate, the activity of 6PGDH is much 
more stable against inactivation by seven proteolytic enzymes, acid, heat, cystamine, 
DTNB, urea, SDS [33], and different inactivating chemical reagents [34,35-36]. In 
presence of phosphate buffer the order of binding of 6PG and NADP to the enzyme is 
different than in triethanolamine buffer [31] and in the presence of 6PG the reactivity of 
several 6PGDH thiol groups with DTNB is reduced [45]. Again, 6PG increases the 
reactivity with periodate-oxidized NADP [37,29].  
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Figure 12: Alternating site co-operativity model for the enzyme 6PGDH. "INT" is the reaction 
intermediate after the redox reaction while "Ru5P" represents both the enolic and the ketonic form of 
ribulose-5-phosphate. According this hypothesis, 6PG binds to one (B) of the two structurally equal 
subunits, inducing in both a different conformational change (step 1). Also NADP binds to the same 
subunit. Subunit B catalyzes (step 2) the redox reaction producing the intermediate and NADPH. Now 
6PG binds to subunit A (step 3) inducing in both subunits a conformational change which promotes 
subunit B to catalyze the decarboxylation of the intermediate. The reaction goes on, till the products 
release, then at the binding of NADP to subunit A (step 4), in the A subunit an other cycle begins, with 
the redox reaction (step 5) producing NADPH and the intermediate. The steps 6 and 7 are a repetition of 
phase 3 and 4, but the subunits have the roles reversed. 
 
 
6.b.3 Isomerization and allostery 
2
H and 
13
C isotope effects have shown the both dehydrogenation and decarboxylation steps 
are partially rate limiting, whereas solvent isotope effects have highlighted a kinetically 
significant isomerization step preceding dehydrogenation, which is also partially rate-
limiting [ 56; 57; 58].  
Even in the reverse reaction an isomerisation step preceding the chemical steps is partially 
rate-limiting but 6PG is able to allosterically activate the reaction, by increasing the 
affinity for the Ru5P [74] 
 
 
6.b.4 Other significant effects along the reaction 
Binding of 4-phospho-D-erythronate (4PE) decreases the dissociation constant of the 
coenzymes bytwo orders of magnitude. In a similar manner, the Kd value of 4PE in the 
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presence of the coenzymes decreases by two orders of magnitude till 18 nM. The results 
suggest that 4PE mimics the transition state of dehydrogenation and that 6PGDH 
undergoes other significant conformational changes along this step of the reaction [19]. 
However crystallographic data do not show any significant conformational change upon 
binding of substrate or coenzyme. Instead, all data before described indicate that the 
binding of the substrate and intermediates modifies in part the conformation of the enzyme 
in solution, making it, perhaps, more rigid. 
 
 All the crystallographic data were obtained with crystals prepared in ammonium sulphate. 
In the crystals each enzyme subunit has firmly bound three sulphate ions[39]; each of these 
ions bridges different segments of the protein chain in the same or in a different subunit 
stabilizing the conformation of the enzyme. Two of these sulphates bind to the active site 
and one is displaced by 6PG. The finding that the enzyme in the crystals does not show 
conformational change in presence of 6PG could be due to the fact that these changes were 
already induced by bound sulphates. 
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Aim of the Thesis 
 
The aim of the thesis is to acquire functional and structural information suitable for a more 
efficient design of inhibitors for 6PGDH from T. brucei. 
The thesis is divided into two parts, which concern, the first, about structural studies on T. 
brucei 6PGDH, and, the second, about functional studies on the enzyme. 
 
1) Structural studies 
Much discrepancy exists between the fixed crystallographic picture of 6PGDH and the 
ligand-induced significant properties of the enzyme. For instance, overlays between the X-
ray structures of 6PGDH alone and in binary complexes with either 6PG or coenzymes 
result in a r.m.s.d. of 0.22 Å for C

 and 0.6-0.7 Å for all atoms, suggesting that ligand 
binding does not modify enzyme conformation. Nevertheless, compared to free enzyme, 
the enzyme-6PG complex shows lower reactivity toward chemicals, denaturing agents and 
proteolysis, and many other evidences exist on significant conformational changes induced 
by 6PG (see introduction). Some studies of the past years suggested that the T. brucei 
6PGDH might undergo an oligomerization process on particular conditions. One objective 
of the thesis is to study in depth this phenomenon by means of several experimental 
approaches:  
* gel filtration  
* crosslinking with glutaraldehyde 
* dynamic light scattering (DLS) 
* sucrose density gradient centrifugation 
* isothermal titration calorimetry (ITC) studies. 
 
2) Functional studies 
One important information that cannot be obtained from X-ray structures is the protonation 
state of the ionisable residues present in  a specific site. After a catalytic cycle, T. brucei 
6PGDH  requires an intramolecular transfer of a proton. In fact at the end of the reaction 
Lys 185 should become protonated and Glu 192 unprotonated; but for a new catalytic cycle 
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is necessary that lysine is unprotonated and glutamate protonated. Hence an other objective 
of the thesis is to explore the ionisation state and the pKa of  Lys 185 and Glu 192 in the 
free enzyme and in the enzyme-substrate complex, by the combined use of site-directed 
mutants and ITC studies. We further explored the ionisation state of  His 188 which is a 
conserved residue at 4-5 Å from Glu 192. 
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MATERIALS AND METHODS 
 
1) Site-Directed Mutagenesis 
We used the technique of site-specific mutagenesis to obtain mutants of interest. (K185H; 
E192Q and H188L) by changing a single nucleotides triplet in the gene of T. brucei 
6PGDH, cloned in the vector of expression pET3a (double-stranded). The complete 
plasmid is called pT7gnd. The plasmids extraction was from bacterial stock JM109 
(genotype: F '[traD36, proAB +, laclq, lacZD (M15)], recA1 edna1 gyrA96 thi hsdR17 
supE44 relA1 D (lacproAB).  
 
The stock JM109 has been used for cloning of the gene of the wild type enzyme. 
Quick Change II site-directed mutagenesis kits were used (Stratagene) (Figure 13). 
 
 
         Figure 13:  Scheme of the QuickChange II site-directed mutagenesis method. 
Mutagenesis was conducted in a double-stranded vector DNA, which was denatured to 
allow the pairing of oligonucleotides with small sequences of the 6PGDH gene of T. brucei 
containing the mutation of interest. (Table 3). 
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K185H 
5‘ 
GGATCATGCGTGCATATGTACCACAATTCG 3‘ 
E192Q 
5‘ 
GATGTACCACAATTCGGGTCAATACGCCATTTTGCAAATCTG 3‘ 
H188L 
5‘ 
GGCGTATTCACCCGAATTAAGGTACATCTTCACGCATGATCCC 3‘ 
Table 3. Primer oligonucleotides synthetized by MWG-biotech AG. 
 
For each mutation two primers were used, complementary to opposite strands of the 
vector, both containing the desired mutation. With dNTP and a PfuUltra ™ High Fidelity 
(HF) DNA polymerase two new chains are synthesized, generating plasmids bearing the 
mutation, containing "nicks" arranged at intervals (Table 4). The temperature cycling used 
is indicated in Table 5. 
 
 
                                 
Table 4: The protocol reaction 
 
          Table 5: The temperature cycling 
reaction buffer (10X) 5μl 
dsDNA template (5 -50 ng) 2 μl 
Forward Oligonucleotide (125 ng) 12.5 μl 
Reverse Oligonucleotide (125 ng) 12.5 μl 
dNTP mix 1 μl 
ddH2O to a final volume of a 50 μl 
di PfuTurbo DNA polymerase (2.5 U/μl) 1 μl 
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After primer extension, the reaction mixture was placed on ice for 2 minutes to cool to ≤ 
37°C. 
The vector filaments moulds were removed using Dpn I endonuclease (target sequence: 5'-
Gm6ATC-3 ') which is able to digest the methylated  and  hemimethylated DNA (the DNA 
isolated from almost all strains of E. coli is methylated). In this way only the newly 
synthesized DNA containing the mutation was selected. Dpn I endonuclease (10U/ μl), was 
mixed with the reaction solution gently by pipetting the solution. The reaction mixtures are 
then spun down in a microcentrifuge for 1 minute and immediately incubated  at 37°C for 
2 hours to digest the parental supercoiled dsDNA. 
Finally mutated carriers must be repaired by removing the "nicks" and amplified. 
Therefore, the vectors containing the desired mutations were transformed into XL1-Blue 
supercompetent cells. The supercompetent cells are gently thawed on ice, for each sample 
reaction to be transformed an aliquot of 50 μl were put in a tube and 1 μl of the Dpn I-
treated DNA is transferred. The transformation reactions were gently swirled and 
incubated on ice for 30 minutes, then heat pulsed for 45 seconds at 42°C and after placed 
on ice for 2 minutes.  0.5 ml of NZY+ broth preheated to 42°C was added (NZY+ broth: 
10g of NZ amine, 5g of yeast extract, 5g of NaCl, 12.5 ml of 1 MgCl2, 12.5 ml of 1 M 
MgSO4 and 20ml of 20% (w/v) glucose per liter, adjusted to pH 7.5). 
 The transformation reactions were then incubated at 37°C for 1 hour with shaking at 225-
250 rpm. 250 µl of each transformation reaction was plated on agar /antibiotic, then put at 
37 ° C for > 16 hours. 
The following steps were the extraction of plasmidic DNA from a single colony and 
sequencing of the entire coding region of mutants T. brucei 6PGDH to check that only the 
single mutation was present, using the dideoxynucleotide chain-termination method. Once 
mutated sequence was obtained, it was introduced into E. coli strain BL21 (DE3) for 
inducible expression. 
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2) Overexpression of the T. brucei enzyme in E. coli. 
 PT7gnd is a plasmid obtained from cloning of the gene gnd (encoding 6-
phosphogluconate dehydrogenase) into the vector pET3a, with the ATG initiation codon 
oriented adjacent to the bacteriophage T7 RNA polymerase promoter. BL21 (DE3) are E. 
coli cells with the phage DE3 encoding T7 RNA polymerase under the control of the 
lacUV5 promoter. 
15 ul of transformed bacteria (stored at -80 °C in glycerol) were added to a Petri dish with 
agar, then left overnight at 37 °C. The next day a single colony was taken and added to 16 
ml LB/16 ul amp (Luria Bertani broth plus ampicillin: 10g tryptone, 5 g yeast extract, 10 g 
NaCl water until 1 liter) and stirred overnight at 37 °C. 
The 16 ml of the preculture were added to 400 ml of LB/amp, and incubated at 28 °C with 
shaking until the culture reached an optical density of 0.6 at 600nm. At this time the 
inducer IPTG (the lac operon inducer isopropylthiogalactopyranoside) was added to the 
culture to a final concentration of 0.4 mM. After adding IPTG , cultivation was left at 28 
°C under shaking for 4 hours. 
Then cells were centrifuged at 4000 rpm for 10 minutes at 4 °C. Pelleted cells were 
resuspended in buffer TEA (50mM TEA; 0.1 mM EDTA; 1 mM mercaptoethanol, pH 7.5) 
to a final volume of 20 ml and stored at -80 °C. 
 
3) Purification of 6-PGDH wt / mutant of T. brucei by bacteria E. coli 
 
The recombinant T. brucei 6PGDH, overexpressed in Escherichia coli, was purified 
according to a technique that was slightly modified compared to the original of Barrett [2]  
After keeping at -80 °C the bacteria were sonicated (XL2020 model sonicator, Heat 
Systems,  power level to 4, 5 short bursts of 10 sec, followed by intervals of 20 sec for 
cooling, keeping the suspension at all times on ice). 
Cell debris and insoluble material were then spun down (40,000 rpm, 30min). The 
supernatant was applied to a 15 ml DEAE-Sepharose column equilibrated with TEA 
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buffer, which was then washed with the same buffer and the flow through material 
absorbing at 280 nm was loaded directly onto a 5 ml 2‘,5‘-ADP-Sepharose column, 
equilibrated with TEA buffer diluted 10 x.  
After washing with the same buffer, the enzyme was eluted with natrium pyrophosphate 
(Na4P2O7) 150 mM containing 1mM EDTA pH 7.2 and the specific activity assayed in 
buffer containing 0.6 mM 6PG and 0.26 mM NADP
+
. 
The whole purification lasted less than one day and was monitored both by SDS-PAGE 
and activity assays. Enzyme was stored in the presence of 50% glycerol at -20°C. 
 
4) Determination of protein and 6PGDH wt/mutant concentration 
 
Spectrophotometric measurements were made throughout with a Jenway 6715 or a 
Kontron Uvikon 930 spectrophotometer or a Tecan infinite 200 microplate reader. Protein 
fluorescence was measured with the same microplate reader. 
The protein purification fractions were measured spectrophotometrically at a wavelength 
of 280 nm for determination of the protein concentration assuming that a solution 
containing 1mg/ml of protein have an absorbance of 1 O.D. A solution containing 1 mg/ml 
of pure 6PGDH has instead at 280 nm an absorbance of 1.023. Knowing that each 
monomer unit of the T. brucei 6PGDH weights 52 kDa we can calculate that 1 mg of 
protein contains 19.2 nmoles. Therefore 1 mg/ml of the enzyme corresponds to a 19,2 
microM concentration having an absorbance at 280 nm, 1.023 O.D. 
To facilitate the storage of samples, the fractions were concentrated by the technique of 
ultrafiltration using Amicon Ultra-15 Centrifugal Filter Devices (Millipore) at 4000 rpm. 
The concentrated samples are assayed for the concentration and stored in 50% glycerol at -
20 ° C. 
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5) Enzyme activity. Assay of activity for 6PGDH  
 
The assay is based on the measurement of kinetics of a reaction mixture containing the 
6PG substrate (0.6 mM), the NADP cofactor (0.26 mM) and our enzyme at a proper 
dilution; in 50 mM TEA buffer with 0.1 mM EDTA at pH 7.5, we proceeded to measure at 
a wavelength of 340 nm the amount of NADPH produced (product of the reduction of the 
cofactor NADP.) The absorbance value is divided by the molar extinction coefficient of 
NADPH which is 6,220. 
The international unit of enzyme activity (IU) is the amount of enzyme which catalyzes in 
one minute, the formation of one micromol NADPH  in standard conditions (25 °C and pH 
optimum). The specific activity of the enzyme has been calculated as the number of UI 
divided by the number of mg of protein. 
 
6) Cysteines reactivity 
The method G. Ellman reaction, 59  is based on the capacity of sulphidrilic groups of 
cysteines to react with 5,5-ditiobis-2-nitro benzoic acid (DTNB), developing a 
spectrophotometrically measurable complex at the wavelength of 412 nm. The method is 
rapid and the stoichiometry is 1:1, coloured product : thiol. Before the reaction, enzyme is 
freed from glycerol, by gel-filtration or dialysis, and used at a concentration 6 microM. 
DTNB is used at a concentration of 4 mg/ml and prepared in natrium phosphate buffer 0.2 
M. Labelling has been measured for 45 min. The product molar extinction coefficient is 
13,600. 
 
7) Polyacrylamide gel electrophoresis (SDS-PAGE) 
The polyacrylamide electrophoresis was performed following the method described by 
Laemmli [60 ] using a 8 x 10 cm gel in a socket for vertical electrophoresis. 
The electrophoretic technique involves the preparation of two mixtures: one for the 
stacking gel which is at the top of the complete gel, in which the concentration of 
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acrylamide is 5% (w/v) and pH 6.8, and the second for the running gel which is under the 
stacking gel, in which the acrylamide concentration varies depending on the chosen pore 
size and the pH is 8,8. The running gel is the gel where protein separation is performed. In 
our case the acrylamide concentration used was 10% to verify the purification of the 
enzyme while both 10 and 7.5% for cross-linking experiments. 
Running Gel (10%) 
1.5 ml of 40% acrylamide buffer (39.3% acrylamide, 0.7% methylenbisacrylamide) 
1.5 ml of TrisHCl (Tris-hydroxymethyl-aminomethane) 1.5 M pH 8.8, 
15 µl of 6.6 M TEMED (N, N, N ‗, N‘-tetramethyethylenediamine) 
2.9 ml of water 
60 µl of SDS (sodium dodecyl  ulphate) 10% w/v, 
30 µl of ammonium persulphate 10% w/v. 
 
Running Gel (7,5%) 
1.125 ml of 40% acrylamide buffer (39.3% acrylamide, 0.7% methylenbisacrylamide) 
1.5 ml of TrisHCl 1.5 M pH 8.8, 
15 µl of 6.6 M TEMED  
 3.26 ml of water 
60 µl of SDS 10% w/v, 
30 µl of ammonium persulphate 10% w/v.  
 
The solution of the running gel was poured between the two glass panes and left to 
solidify. 
In this period it was prepared the stacking gel solution 5% (w/v) as indicated in Table 6. 
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500 µ l acrylamide buffer 20% (19.6% acrylamide, 0.4% methylenbisacrylamide) 
500 µ l 0.5 M TrisHCl  pH 6.8 
8 µ l 6.6 M di TEMED  
930 ul of water 
20 ul SDS 10% w/v 
20 µ l ammonium persulphate 10% w/v. 
Table 6: the stacking gel solution 5% (w/v) 
The solution of the stacking gel was poured over the polymerized running gel and the 
spacer comb for the wells was fitted between the two panes. Then the gel was left to 
polymerize. After, spacer was removed and the gel was installed in the device for 
electrophoresis, the tray containing the electrodes was filled with running buffer (25 mM 
Tris, 192 mm glycine, 0.1% SDS, at pH 8.3).  
The samples were denatured before to be loaded into the wells. Buffer of denaturation 
(12.5% v/v 0.5 M Tris pH 6.8, 2% w/v SDS, 5% v/v β-mercaptoethanol, 10% v/v glycerol) 
containing a small amount of bromophenol blue as a tracer, was added to samples and then 
these were brought to 90 °C for 4 min. After denaturation 20μl of each sample was applied 
to the wells of the gel. 
The electrophoresis was conducted by applying a current of 25 mA until the tracer had 
reached the lower limit of the gel, (power supply parameters: 0.46 KV, 25mA, 35 W, 45-
50 min). 
Since the run was done in the presence of SDS, the samples acquired the same negative 
charge and the migration is according the relative molecular weight of the sample. 
After the run was completed  the gel was extracted from the support and stained with 
Comassie blue C250 coloration without methanol (Table 7). 
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 In 1 liter of bidistilled water 
 80 mg of Coomassie Brilliant Blue G-250 
 HCl in 40 mM final concentration. 
Table 7: Coomassie blue C250 without methanol. 
The gel in the dye solution was put in a microwave oven for 2-3 cycles of 15 seconds at 
maximum power. Then it is left in slow shaking for about 15 minutes at room temperature. 
Finally, the dye was removed and gel is soaked in distilled water at room temperature, 
rinsed several times and left in water in gentle agitation. Densitometric analysis of the gel  
was done with the program Quantity One (Biorad). 
 
8) Gel Filtration  (Sephacryl S-200 HR and AcA 34) 
In gel filtration chromatography – also known as size exclusion chromatography – 
separation is based on differences in the size and/or shape of the analyte molecules, which 
governs the analytes‘ access to the pore volume inside the column packing particles. The 
exclusion limit of a size exclusion packing indicates the molecular weight, for a particular 
polymer type, above which analytes are fully excluded from entering the pores and thus 
will not be separated. According to their size, smaller analytes have partial to complete 
access to the pore volume. Larger molecules with less access to the pore volume elute first, 
while the smallest molecules elute last. The fractionation range means that molecules 
within that molecular weight range can be separated. 
In the study, two gel filtration matrices were used: Sephacryl S-200 from GE Healthcare 
and ACA-34 Ultrogel from LKB. Sephacryl High Resolution is a cross-linked copolymer 
of allyl dextran and N,N‘-methylene bisacrylamide, which can separate proteins in the 
molecular weight range 5 × 10
3
 – 2.5 × 105 Da. The diameter of the Sephacryl column was 
0.7 cm and height 16.5 cm. The flow rate was of 3.3 microl/sec.  
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ACA-34 Ultrogel is polyacrylamide/agarose with a linear fractionation range of 20-350 
kDa and an exclusion limit of 750 kDa for globular proteins. The diameter of the column 
was 0.8 cm and  height 20 cm (7.6 ml of resin). The flow rate was of  210  microl/sec.  
Calibrations were performed with aldolase (160 kDa), bovine serum albumin (66 kDa), 
beta-lactoglobulin (35 kDa).  
Columns were equilibrated with 50 mM triethanolamine, pH 7.5, 0.1 mM EDTA and 1.0 
mM 2-mercaptoethanol. 20-40 microl of protein at a subunit concentration of 50 microM 
(about 3 mg/ml) were loaded onto the columns. The effect of ligands was determined by 
equilibrating the column with 70 microM NADP(H) or/and 0.16 mM 6PG. 4PE was used 
at 0.16 mM. Ligands were added to the enzyme sample before column loading to the same 
final concentrations used for the columns or higher. Eluted fractions were collected in 
opaque-walled plate, with 100 microl/well and a total of 24 fractions. Protein detection was 
by measure of the protein fluorescence, due essentially to tryptophans, using an excitation 
wavelength of 280 nm and an emission wavelength of 340 nm. The emission at 340 nm is 
proportional to the concentration of the sample, in this way we were able to locate the 
wells containing the eluted sample and create a curve of elution. 
 
9) Chemical cross-linking of 6PGDH 
Many biochemical and biophysical methods can be used to characterize the 
oligomerization state of proteins. One of the most widely used is glutaraldehyde cross-
linking.  The simplicity of the procedure, which requires only the mixing of glutaraldehyde 
with the protein solution  and the availability of glutaraldehyde as a common reagent easily 
found in a biochemical laboratory, and the direct detection of cross-linked products by 
SDS–PAGE have led to the wide application of this method.  The major limitation of the 
technique arises from the non-specificity of the reagent, which can react with all the 
nitrogens of a protein and mainly with lysines, tyrosines, histidines, and arginines  and . 
Intra- and intermolecular links are formed that could connect atoms of neighboring but not 
interacting molecules, yielding artificial protein oligomers that lack biological significance. 
To eliminate the possibility of artificial interactions, the proper reaction conditions must be 
established through a detailed and often time-consuming investigation of the influence of 
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many parameters such as protein concentration, reagent concentration, temperature, and 
time of reaction 61 
Glutaraldehyde is a linear, 5-carbon dialdehyde. It reacts rapidly with amine groups at 
around neutral pH 62 and is more efficient than other  aldehydes in generating thermally 
and chemically stable crosslinks. 63. It is a bifunctional reagent because two aldehyde 
groups can react with two amino groups via Schiff base (Figures 14 and 15). 64 
 
 
Figure 14: Reaction of the amino groups of proteins with glutaraldehyde. 
 
The simple structure of glutaraldehyde is not indicative of the complexity of its  ehaviour 
in aqueous solution and its reactivity. The structure of glutaraldehyde in aqueous solution 
has been the subject of more debate than any of the other crosslinking reagents. In fact, 
glutaraldehyde structure in aqueous solution is not limited to the monomeric form (Figure 
16) 63, it can also undergo intramolecular cyclization, for instance producing pyridines 
(Figure 15). At alkaline pH polymerization of glutaraldehyde makes possible Michael-type 
additions with the formation of other types of condensation with amino groups (Figures 15 
and 16). 
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 Figure 15: Formation of pyridine rings after the reaction 
of glutaraldehyde with amino groups of proteins. 
Glutaraldehyde cross-linking was performed at different concentrations of enzyme and 
glutaraldehyde. The concentrations range were 0.1-1 mg/ml for the enzyme and 0,05-5 % 
for glutaraldehyde. Reaction was in 0.04 M sodium pyrophosphate, 25 mM HEPES (pH 
7.5), containing 0.5 mM EDTA. Different incubation times (1, 2, 3, 5 minutes) were 
assayed and the reaction was stopped by adding 40 µl of 1 M TRIS/HCl pH 8.0. Aliquots 
were then resolved by either 7,5% or 10% SDS-PAGE. The more efficient cross-linking 
condition was with a final 1 % glutaraldehyde (by mixing 0.5 ml of enzyme with 20 µl of 
25 % glutaraldehyde). Cross-linking was made also in presence of either 40 µM NADPH 
or both 40 µM NADPH and 1mM 4PE. 
 
Figure 16: Summary of the possible forms of glutaraldehyde in aqueous solution. 
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10) Dynamic Light scattering (DLS) measurements 
DLS may be used as a complementary tool for characterization of proteins. This technique 
is used for measuring the size and size distribution of molecules and particles typically in 
the submicron region, and with the latest technology lower than 1 nm.  66.    
It is a relatively fast method of characterizing the size of biomolecules in solution, taking 
only minutes for a measurement.  It may be used to distinguish between a homogenous 
monodisperse and an aggregated sample. Quite frequently in nature, oligomeric states exist 
in equilibrium in solutions of  biomolecules 65.    
When light passes through a solution containing molecules, depending on the optical 
parameters of the system, part of the light will be scattered. This scattered light may be 
analysed either in terms of its intensity or in terms of its fluctuations. The former type of 
analysis is called static light scattering and may be used to find the molar mass and radius 
of gyration. However, for many typical biomolecules (< 20 nm), the radius of gyration is 
not easily measurable since only a minor angular variation in the intensity is exhibited. 
This means that measurements may be performed at a single angle, provided the 
concentration and the refractive index are known. 
The DLS technique is capable to detect the fluctuations of the scattering intensity due to 
the Brownian motion of molecules in solution. 67 Thus it measures the diffusion of 
particles moving under Brownian motion, and converts this to size and a size distribution. 
The wave vector determines the length scale over which molecular motions are detected 
and it is given by:  
   q = 2πn sin(2)/    Equation 1:  The wave vector 
 
where n is the refractive index of the buffer, λ is the wavelength of the radiation, and 
θ the scattering angle.  
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In our case (Zetasizer Nano S, Malvern) the light source is He-Ne laser 633nm, allowing a 
size measurement range 0.3nm – 10.0 microns (diameter) and a molecular weight range 
980 Da – 20 MDa. 
The dynamic information of the particles is derived from an autocorrelation of the intensity 
trace recorded during the experiment. 
The resulting correlation function is: 
     
. 
where g
2
(q;τ) is the autocorrelation function at a particular wave vector, q, and delay time, 
τ, and I is the intensity. 
 
It is expected to show — under ideal conditions — a single exponential decay 
   
where the decay rate Dq
2
 includes the diffusion coefficient D of the molecules, and the 
fitting parameter β is related to the ratio of coherent signal to incoherent noise .  
The Stokes-Einstein relation may be used to convert the measured diffusion coefficient 
(equation 4) into a hydrodynamic diameter dH which is the size of a sphere that has the 
same diffusion behaviour. 
 
 
Equation 3: Equation for single      
exponential decay for the correlation 
function G 
 
Equation 2: Correlation function. of 
the scattering signal. The correlation 
is based on the measurement of the 
intensity in function of  time 
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In the Stokes-Einstein relation, T is the absolute temperature, KB  the universal Boltzmann 
constant  and η, the viscosity of the buffer. 
In the end a z-average or cumulant average, particle diameter is recovered. A polynomial 
fit to the logarithm of the function leads to the size (the first cumulant) and its deviation 
(the second cumulant), where the polydispersity index PDI corresponds to the square of the 
normalised standard deviation of an underlying Gaussian size distribution. 
Mean hydrodynamic radius measurements were compared with value calculated by the  
Hydropro software 68 
 
Measurements were carried out on: 
 free enzyme 
 binary complex: enzyme-NADPH 
 tertiary complex: enzyme-NADPH-4P-erythronate 
Measurements were performed at 25 °C or  5 °C. 
The measurements were made at the Department of Biochemistry, University of Verona. 
The buffer used for measurements was 50 mM Triethanolamine (TEA), pH 7,5 with 0,1 
mM EDTA and 1 mM 2-mercaptoethanol, filtered immediately before use to eliminate 
impurities. 
The protein concentration used were 2 and 20 microM .  The concentrations of NADPH 
and 4PE were 0.2 mM and 0.5 mM, respectively. 
 
 Equation 4: The Stokes-Einstein relation used to 
convert the measured diffusion into a 
hydrodynamic diameter dH  
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11) Sucrose-density-gradient centrifugation 
 
Sucrose density gradient ultracentrifugation is a powerful technique for fractionating 
macromolecules like DNA, RNA, and proteins. To this purpose, a sample containing a 
mixture of different size macromolecules is layered onto the surface of a gradient, whose 
density increases linearly from top to bottom. During centrifugation, different size 
macromolecules sediment through the gradient at different rates. 
 
 The rate of sedimentation depends, in addition to centrifugal force, on the size, shape, and 
density of the macromolecules, as well as on the density and viscosity of the gradient. In 
this way, macromolecules are separated by size with larger ones sedimenting towards the 
bottom and lighter ones remaining close to the top of the gradient. 69 
 
Fractionation studies by sucrose density gradient was widely used in the molecular weight 
determination of proteins. 
On top of a 11.2 ml discontinuous sucrose gradient with 5 %, 10 %, 12.5 %, 15 %, 20 % 
and 35 % (w/v) cushions, 0,1-0.2 ml of sample, free of glycerol, at a concentration of 1 
mg/ml was layered and centrifuged at 38,000 rpm for 19 h at 4°C, by using the swing-out 
rotor SW40 in a Beckman XL-70 ultracentrifuge. Sucrose solutions were prepared with 
0.05 M triethanolamine, pH 7.5, with 0.1 mM EDTA and 1 mM 2-mercaptoethanol, with 
or without ligands. 
 During every cushion preparation, tubes were weighted till the same weight was reached, 
then tubes were put at -80°C. The second cushion was stratified onto the first when it was 
freezed. The centrifuged solution was fractionated into 70 fractions from the bottom, by 
laminar flow within a subtle flexible plastic tube connected to glass capillaries with a 
diameter of 1 mm, at the two ends (Figure 17). Some tubes contained, as molecular weight 
markers, lactate dehydrogenase (140 kDa) and bovine serum albumin (66 kDa). The rotor 
was decelerated with the brake off. 
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  Figure 17. : Collecting of the fractions after the density-gradient 
                                 centrifugation. 
 
12) Isothermal titration calorimetry (ITC)  
Isothermal titration calorimetry (ITC) is a well established technique that can determine the 
enthalpy of a binding interaction (ΔH), the binding affinity (Ka) and stoichiometry in a 
single experiment. Also the entropy (ΔS) and free energy (ΔG) changes are detected. ITC 
works by titrating one reactant with a second reactant under isothermal condition. The 
signal measured is the heat released or absorbed upon interaction (binding) of the two 
reactants. A series of injections are performed and the heat signal will approach zero as the 
limiting reactant becomes saturated. Fitting of the isotherm gives the thermodynamic 
parameters 70.  
To this end the calorimeter goes to directly measure the heat (released or absorbed) 
associated with a reaction, which, at constant pressure, is equal to the enthalpy change in 
this process, the ΔH. 
When two molecules bind, heat released or absorbed is proportional to the increase in 
complex concentration. At the end, saturation of the protein is reached and any signal of 
heat is due to the background noise. 
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The instrument consists of two identical cells surrounded by an inner shield and an outer 
one, and a injecting syringe loaded with the solution of one ligand (Figure 18). 
These two coatings are maintained at the same temperature of the cells to minimize heat 
flows from or to the cells. The measurement of the heat released or absorbed is performed 
by two control systems concatenated, placed both on the cells and on the coats that 
surround them. The first measures the difference in temperature between the two cells, 
while the second system measures the temperature difference between the cells and the 
outer casing. The temperature in the reference and the sample cell is kept identical, 
subtracting or providing heat to the sample cell. The integral of the power supplied to 
maintain constant over time ΔT1 (the difference in T between the two cells) is a function 
of the total heat involved in the reaction. 
A VP-ITC microcalorimeter (Microcal, Northampton, MA, USA) was used. 
 
 
Figures 18 : Schematic representation of a VP-ITC microcalorimeter and the syringe . 
 
A sequence of injections is programmed and the solution of the ligand periodically is 
injected in the sample cell.  
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Because some proteins aggregate at the high concentrations needed for the species in the 
injection syringe, most often the protein is loaded into the sample cell. The optimal 
macromolecule concentration is at least 10 fold higher than the predicted affinity of the 
system, though it is possible to get accurate data for weak-binding systems under specific 
experimental conditions with concentrations below. 
The concentration of the ligand should be large enough (7-25 fold more concentrated than 
the Kd for the weakest ligand binding site) so that saturation occurs within the first third to 
half of the titration. Accurate fitting of the data also requires saturation of the signal. For 
systems with higher binding affinity, a lower ligand concentration should be used to avoid 
saturation too early in the titration, which will give inaccurate fits. Once the heat of 
dilution control (i.e. titration of ligand into buffer) has been subtracted from the titration, 
the enthalpy at saturation should approach zero. 70. 
It is important to know the precise concentration of the sample in the ITC cell and of the 
ligand in the injection syringe. 
A typical analysis with ITC calorimeter is characterized by several stages: 
a) Preparation of the samples (enzyme and ligand in our case) 
b) Setting up the Experiment 
c) Data processing using software provided by the OriginTM 
 
12.a) Samples preparation 
12.a.1) Enzyme preparation 
- The enzyme was dialyzed overnight against buffer to remove glycerol 
- After dialysis the enzyme is centrifuged 
- The supernatant is diluted in dialysis buffer till 1,85 to 2 ml  
- Spectrophotometric measurement at 280 nm of the concentration of the 
enzyme is done 
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 12.a.2 ) Ligand preparation 
 
- NADP, NADPH and 6PG were diluted in dialysis buffer  
- Measurement of the concentration of the ligand is determined 
spectrophotometrically 
 
Before to be loaded into the instrument both sample and ligand, are degassed. 
 
 
12.b) Setting up the Experiment 
 
- The sample cell is rinsed two or three times with 1.8 ml of distilled water 
using the proper  syringe 
- 1.8 ml of macromolecule solution is loaded in the sample cell being careful 
to avoid bubble formation 
- The reference cell is filled  with distilled water or buffer. 
- The syringe is accurately loaded with the ligand and after removal of any 
bubble inside, is placed into the sample cell 
 
Parameters for running are set up in the ITC computer (primarily temperature): 
- Number of injections = 23 
- Injected volume = 10 µl 
- Time spacing between each injection = 380 seconds 
- enzyme concentration = 0,012 mM  
- ligand concentration = 0,150 mM for NADPH 
                                                 0,5 mM for NADP 
                                                 1,74 mM for 6PG 
 
It was made a pre-injection of 5 µl and the result from it was not used for data analysis. 
The different buffers used, with their ionization enthalpy, are reported in Table 8. 
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Buffer  pK 
ΔH (kcal*mol-1) 
at 25 °C Buffer pH range  
MES 6,07 3,71 5.5–6.7 
MOPS 7,09 5,21 6.5–7.9 
HEPES 7,45 5,03 6.8–8.2 
TRIS 8,1 11,3 7.5–9.0 
TEA 7,8 8,028 7,3-8,3 
               Table 8: pK and ΔH ionization of buffers used 
 
12.c) Data processing  
After correction for dilution enthalpy and for any noise, which was opportunely removed, 
together with the first point, from the raw thermogram, data were fitted by nonlinear least 
squares fitting using the software provided by the instrument manufacturer OriginTM (7) 
to determine: 
-  the equilibrium constant of association, Ka 
-  the enthalpy of binding, ΔH 
- the stoichiometry of the binding, n 
- the entropic contribution to the free energy of binding, ΔS 
 
From the initial measurements the Gibbs free energy (ΔG), and entropy change (ΔS) are 
calculated using the equations: 
 
 ΔG = -RT ln K        Equation 5: the Gibbs free energy 
(in which R is the gas constant and T is the temperature in Kelvin degrees) 
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 ΔG =  ΔH-TΔS        Equation  6: the Gibbs free energy 
 
Since the buffers are able to take or release protons based on their ionization enthalpy, the 
value of enthalpy calculated by the instrument is corrected taking into account the enthalpy 
of ionisation of the buffer used. The enthalpy of binding independent from buffer ΔH0 [71 
was calculated by the equation: 
 
     ionobs
HnHHH  0             Equation 7: Observed enthalpy equation    
        ( obsH ). 
from which we can obtain the binding enthalpy independent of the buffer (ΔH0)  
where ΔHion  is the enthalpy of ionisation of the buffer used,  ΔH0 is the enthalpy 
measurable in a buffer with  ΔHion=0, and  nH+ is the number of hydrogen ions released or 
captured. 
 
The ionization enthalpy dependence from the temperature is according Fukada and 
Takahashi [72 
The number of hydrogen ions released or taken is calculated from the equation: 
 
   
21
21
ionion
ossoss
HH
HH
nH



                  
 
     Equation 8: To calculate the number of 
hydrogen ions  released or taken.          
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where ΔHoss and ΔHion are the enthalpy of binding observed experimentally and the 
enthalpy of ionisation of the buffer,  respectively. 
 
12.c.1)  Changes in heat capacity ( ΔCp°) 
Changes in heat capacity (ΔCp°) are calculated from the slope value of the linear 
correlations between the buffer-independent enthalpy change ΔHo for binding and 
temperature [73]. 
 For the formation of a protein-ligand complex, the ΔCp and ΔH can also be calculated 
from the changes in the polare and apolar solvent exposed surface area (ΔASAp and 
ΔASAap) [73]. (see equation  9) 
 
 
    ΔCp = 0.45 ΔASAap-0.26 ΔASApol             
 
 
 
ΔH(60) = -8.44 ΔASAapol + 31.4 ΔASApol        
 
where ΔASA indicates the variation of accessible surface area.  
Knowing the ΔCp and the ΔH at any temperature, one obtains a system of two equations 
with two unknowns values,  (ΔASAapol  and ΔASApol), which can be easily solved.  
ΔASAapol  and ΔASApol for both the NADP and NADPH binding can also be calculated 
with the NACCESS program [84, using a probe (sphere) radius of 1.4 Å and a slice width 
     Equation 9: To calculate changes in heat 
capacity from  exposed surfaces variations 
(polar / apolar) 
Equation 10: reference value obtained at the 
temperature (60 °C), considered the average 
denaturing temperature for globular proteins 
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of 0.1 Å from the structures of sheep liver 6PGDH bound to either a NADP analogue 
(PDB ID 1PGN) or NADPH (PDB ID 1PGO).  
 
12.c.2 ) Effect of pH on dissociation constant 
When the binding between the protein and the ligand occurs only in a precise state of 
ionization, the apparent dissociation constant varies as a function of pH. If only the 
protonated form of the protein binds the ligand according to the scheme: 
P
-
  +  H
+
  <=> PH + L <=>  PHL 
decreasing the pH, shifts the equilibrium to the right and the apparent dissociation constant 
decreases. The intrinsic dissociation constant is then: 
     
pKa
H
H
app
a
a
KK





10
int
                  
 
where aH+  is the activity of hydrogen ions and is equivalent to 10
-pH
. In a similar way we 
proceed if the ligand is present in different states of ionization  
 
 
12.c.3 ) Effect of pH on binding enthalpy 
The capture/release of hydrogen ions varies depending on the pH, and is also dependent on 
the change of the pKa of the ionizable groups in the ligand-protein complex compared to 
the isolated protein: 
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Equation 11: The intrinsic dissociation 
constant. 
 
Equation12: The capture/release 
of hydrogen ions depending on 
the pH and pKa 
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where  C
iK  and 
F
iK are the Ka of the ionizable groups in the complex and in the free 
protein, respectively.  
Also 
 
 
Where H   represents the number of hydrogen ions respectively linked to the complex and 
the free protein. 
 
 H0  includes the enthalpy changes related to the phenomena of protonation / 
deprotonation of the protein, and the intrinsic enthalpy of binding Hint between the ligand 
and the protein in the correct final state of protonation, will be given by: 
 
 
 
where HC and HF are the enthalpies of protonation of the complex and the free protein, 
respectively. 
Can be transformed in 
      Equation 14: OH  transformed 
 
 
Where H = HC - HF 
FC HHnH 
FFCC
O HHHHHH  int
      Equation 13: enthalpy changes as a 
function of the protonation / 
deprotonation and   the  intrinsic 
enthalpy binding   
cF
O HHHnHHH 

int
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RESULTS, DISCUSSION 
AND CONCLUSION 
 
Part I. Structural studies. Results and Discussion 
 
 
a) Gel-filtration of 6PGDH 
 
We determined through gel permeation chromatography the molecular weight of the T. 
brucei 6PGDH enzyme, which corresponded to a weight of 104 kDa, the same reported in 
the literature for the dimeric enzyme. However, when the columns were equilibrated with 
different ligands, enzyme behavior (in terms of elution volume) varied. 
In the presence of  NADPH a lower elution volume, corresponding to a molecular weight 
of 208 kDa, is observed (Fig. 19A).  
In the presence of NADP the elution volume still corresponds to the dimer  since  no 
change was observed (Fig. 19A). 
In the presence of 6PG, either alone or with NADPH (Fig. 19.B), in both cases the elution 
volume was in a intermediate position compared to the positions obtained in the presence 
of NADP and NADPH.  
In the presence of both 4PE, an analogue of 6PG thought to mimic a reaction intermediate, 
and either NADP or NADPH (Fig. 19.C) the elution volume corresponds to a molecular 
weight of 208 kDa suggesting that the functional ternary complex is a tetramer. 
 
Comparison of the effects of these ligands suggests that the NADPH induces the formation 
of a tetramer (Fig. 19.A) whereas in the presence of 6PG, either alone or with NADPH, 
there is a dimer-tetramer equilibration (Fig. 19.B), shown by the intermediate position 
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between that of the enzyme alone (dimer) and that of the enzyme-NADPH complex 
(tetramer). 
 
.
Figure 19:Gel-filtration profile of T. brucei 6PGDH with and without either NADPH or other 
ligands.A) From AcA-34, equilibrated with and without each coenzyme. B and C) From 
Sephacryl S-200. 6PG(the substrate 6-phosphogluconate), 4PE (the dehydrogenation 
intermediate analogue 4-phosphoerythronate). 
 
The presence of a dimer-tetramer equilibrium induced by ligands in T. brucei 6PGDH was 
further investigated by sucrose density gradient centrifugation, glutaraldehyde cross-
C 
B 
A 
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linking, dynamic light scattering and calculation of heat capacity change by 
microcalorimetry. 
 
 
b) Velocity Sedimentation of 6PGDH 
 
Also this technique indicated that NADPH turns out the enzyme to the tetrameric structure, 
and that in the presence of 6PG the sedimentation behaviour is intermediate between dimer 
and tetramer (Figure 20). It is noteworthy that the enzyme-NADPH complex sediments as 
a wide peak, suggesting that a slow re-equilibration tetramer-dimer occurs during the long 
time of the centrifugation run. This observation is confirmed by the experiments carried 
out at lower enzyme concentrations, that show a significant shift of the enzyme-NADPH 
complex toward the dimer (Figure 21). 
 
 
Figure 20. Sedimentation of T. brucei 6PGDH with and without 0.02 mM NADPH or with both 
NADPH and 0.16 mM 6PG during sucrose-density gradient centrifugation. Arrowheads show 
positions of lactate dehydrogenase (140 kDa, the left one) and bovine serum albumin (66 kDa, the 
right one), used as markers. Protein concentration is around 1 mg/ml. 
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Figure 21. Enzyme concentration dependence of the association reaction between dimers to  
form tetramer for T. brucei 6PGDH, in absence or presence of 0.02 mM NADPH. 
 
 
c) Glutaraldehyde cross-linking of 6PGDH 
 
We cross-linked the enzyme with glutaraldehyde, either in the presence or in the absence 
of 40 µM NADPH. Surprisingly, we were unable to observe any difference between the 
enzyme alone and the enzyme-NADPH complex (Fig. 22 A and B). As shown in Figure 
22A, both samples show a band at ~100 kDa, the dimer, and two more consistent bands at 
200 and 240 kDa. The presence of two bands in the high molecular weight region could be 
due to a different way of cross-linking, more than to formation of larger aggregates. In fact 
it is known that proteins containing disulphide bridges in SDS-PAGE show under non 
reducing conditions a MW larger than under reducing conditions, indicating that the 
presence of  intramolecular cross-linking causes an anomalous migration in SDS-PAGE. In 
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this case the band at 240 kDa could be caused by the presence of cross-linking within the 
same subunit. 
 The lack of a NADPH effect on the cross-linking, and the presence of the high molecular 
weight species, even with low glutaraldehyde concentrations and short incubation times, 
both suggest that the equilibrium dimer-tetramer is already present in the enzyme, 
independently on the ligands presence. In Fig. 22 B also the enzyme not cross-linked is 
shown, which appears as monomer in these denaturing conditions. 
 
 
Figure 22. (A) SDS-PAGE at 7,5 % acrylamide in the resolving gel, of chemically cross-linked 
T. brucei 6PGDH, in the absence and presence of 40 µM NADPH, incubation with 
glutaraldehyde was for 1 min. (B)  SDS-PAGE at 10 % acrylamide in the resolving gel of 
chemically cross-linked T. brucei 6PGDH, in the absence and presence of 40 µM NADPH, 
incubation with glutaraldehyde was for 3 and 5 min respectively. St, protein standards, N.C., 
enzyme not cross-linked with glutaraldehyde (50 kDa). 
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An other experiment is shown in Fig. 23, where enzyme was treated with glutaraldehyde in 
absence or presence of both 40 µM NADPH and 1 mM 4PE, that is in a condition where 
the enzyme is  in abortive ternary complex. Again it appears that the cross-linking reaction 
is very fast. Densitometric analysis indicates that the apparent higher proportion of 
tetramer compared to dimmer in the presence of ligands is not significant  
 
 
Figure 23.  (A) SDS-PAGE of T. brucei 6PGDH, treated for different times with glutaraldehyde (GA). (B) 
Densitometric analysis of the tetramer band. 
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d) Dynamic light scattering 
 
The oligomerization of T. brucei 6PGDH was studied by DLS. As shown in Table 9, the 
average hydrodynamic radius of the enzyme increases by increasing the protein 
concentration, suggesting a concentration dependent association of the protein. However 
the presence of NADPH, or the presence of both NADPH and 4PE, does not affect the size 
of the protein. Again the experiments suggest that the dimer-tetramer equilibrium is already 
present in the enzyme, independently on the ligands presence. A rough calculation of the 
hydrodynamic radius with HydroPro software (3.94 nm) suggests the presence of larger 
molecular weight forms even at low protein concentrations.  
 
 
             Table 9: DLS measurements of mean hydrodynamic radius.                   
a
 R= radius 
 
 
e)  ITC- and  calculation of heat capacity change  
 
NADP and NADPH have a very different behaviour. In fact the enzyme-NADP complex 
shows the same behaviour of the free enzyme, suggesting that NADP binding does not 
modify significantly the rates of oligomerization. To get more information on the 
differences between NADP and NADPH binding, the binding of the dinucleotides was 
characterized by ITC. A titration of T. brucei 6PGDH with NADP in 50 mM Hepes buffer, 
pH 7,5 at 15°C is shown in Fig. 24. The Kd value is 7,54 µM. 
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Figure 24. T. brucei 6PGDH titration with NADP by ITC, in Hepes 
buffer,   pH 7.5 at 15°C. 
 
 
The experiments were performed at pH 7.5 in different buffers, and the buffer independent 
binding enthalpy as a function of temperature is reported in Fig. 25. The slopes of the 
obtained lines give the ΔCp at the binding. There is a remarkable difference between the 
ΔCp for NADP (-92.56 ± 16,28 cal/mol∙K ) and that for the NADPH (-520,35 ± 37,44 
cal/mol∙K). For the formation of a protein-ligand complex, the ΔCp can also be calculated 
from the changes in the polar and apolar solvent exposed surface area (ΔASAp and 
ΔASAap) upon the binding [73]. These changes were calculated with NACCESS program 
from the structures of sheep liver 6PGDH bound to either a NADP analogue or NADPH. 
While for the NADP binding, experimental and calculated ΔCp are superimposable (-92.56 
versus -92.63), for the NADPH binding, the experimental value is very different from that 
calculated (-520.35 versus -201.78). There is a decrease of subunit solvent exposed surface 
at the NADPH binding of ca 2500 Å (Table 10). This suggests that the binding of NADPH 
to the T. brucei 6PGDH causes a conformational change with a large modification of the 
solvent exposed surface area, much greater than that predicted by the crystal structure in 
ammonium sulphate, which may be consistent with the existence of a dimer-tetramer 
equilibrium. 
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Table 10: Comparison between the changes in the subunit polar and apolar solvent exposed surface area 
(ΔASAp and ΔASAap in Å
2
) upon the binding of the coenzymes. 
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Figure 25. Buffer-independent enthalpy change (ΔHo) dependence from the 
temperature for the binding to T. brucei 6PGDH of NADP (A) and NADPH (B) 
respectively. 
  
 
Coenzyme 
ExperimentalASA  NACCESSASA  
ASAap ASAp ASAtot ASAap ASAp ASAtot 
NADP -439 -454 893 -571 -598 -1169 
NADPH -1586 -2063 -3649 -701 -437 -1138 
A 
 
 
 
 
 
 
 
 
 
B 
A 
 
 
 
 
B 
 
 
 
 
 
B 
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 Data till here shown, indicate the presence of a dimer-tetramer equilibrium, but while 
glutaraldehyde cross-linking and DLS do not suggest any effect of NADPH or of other 
ligands on this equilibrium, dynamic experiments (gel filtration and sucrose density 
gradient), where the different oligomeric forms can be separated, show a strong effect of 
NADPH. We explain these data as a NADPH effect only on the kinetics of 
oligomerization. In fact if the dimer-tetramer equilibrium in the free enzyme is very fast, in 
both the gel filtration and density gradient experiments the tetramers dissociate and only 
dimers are observed. Instead, if the binding of NADPH strongly reduces the rate of 
association-dissociation of dimers, the tetramers can be observed. If NADPH affects 
equally the rate of both association and dissociation, the equilibrium dimer-tetramer is not 
perturbed, therefore DLS and cross-linking are unable to evidence the NADPH effect.  
Gel-filtration data indicate that also 6PG reduces the dimers association-dissociation rate, 
even if less than NADPH, and, more interesting, in the presence of 6PG the reduced 
coenzyme is no more able to strongly reduce the association-dissociation rate. The 
antagonism between the substrate 6PG and the coenzyme is a recurrent datum. Examples 
are the 6PG-induced affinity decrease of the enzyme for NADPH and also the half-site 
reactivity of 6PGDH for NADP, in the presence of 6PG, or for NADPH, in the presence of 
4PE. 
To verify whether the ligands effect on the 6PGDH oligomerization is related to other 
peculiar enzyme properties, we studied in some T. brucei 6PGDH mutants, both the 
NADPH effect on the dimer-tetramer equilibrium rates and the presence of the half-site 
reactivity at the ternary complex. 
 
f) Dimer-tetramer equilibrium in 6PGDH mutants 
 Three site-directed mutants were analyzed: K185R and E192Q, where the mutated 
residues are involved in catalysis and having very little residual activity, and C372S, with a 
mutated residue outside from the active site, and a residual enzymatic activity of about 
70%. Despite the great differences in enzymatic activity, all the three mutants show, by 
ITC titration with NADP of the enzyme-4PE complex, a full-site reactivity (almost 2 
NADP binding sites/dimer), in contrast to the WT, which presents a full-site reactivity only 
when the enzyme is not in a binary complex with 4PE (Table 11). Thus, the half-site 
reactivity displayed by the WT in the ternary complex, in the analyzed mutants is 
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completely lost, even in the nearly full active C372S. Gel filtration experiments, in the 
presence and in the absence of NADPH, show that all mutants behave as dimers also in the 
presence of NADPH (data not shown). Thus the half-site reactivity and the rate of 
oligomerization share a common mechanism. 
 
Enzyme Kd (µM) Sites/dimer 
WT 7.54 ± 0.19 1.86 ± 0.13 
WT-4PE 0.043 ± 0.04 1.00 ± 0.003 
K185R 5.7 ± 0.1 1.58 ± 0.06 
K185R-4PE 1.0 ± 0.05 1.64 ± 0.036 
E192Q 2.0 ± 0.09 1.72 ± 0.05 
E192Q-4PE 0.138 ± 0.035 1.51 ± 0.07 
C372S 4.5 ± 0.8 1.74 ± 0.11 
C372S-4PE 0.02 ± 0.017 2.02 ± 0.26 
Table 11: Binding parameters of NADP to 6PGDH from Trypanosoma brucei, in 
Hepes buffer, pH 7.5, at 20°C. 
 
 
Part I. Structural studies. Conclusion 
The physiological significance of the dimer-tetramer equilibrium, and of the effects of 
NADPH and 6PG, is unclear. 6PG has several effects on the 6PGDH: not only it decreases 
the NADPH inhibition by increasing the Kd/Ki [19,75,76], but also it induces the half-site 
reactivity for NADP [19,37], acts as allosteric activator [74], and promotes the 
decarboxylation of the 3-keto intermediate [38]. Furthermore NADPH is not simply an 
inhibitor and a product of the reaction. In fact it promotes the conversion of Ru5P to the 
enolate intermediate in the reverse reaction [77,78], and again promotes the 
decarboxylation of the 3-keto intermediate [38,79]. In the present report we find another 
property of 6PG and NADPH, the effect on the rate of dimer-tetramer equilibrium of the 
enzyme. 
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However the intracellular concentration of 6PGDH is usually low enough to keep the 
enzyme in the dimeric form, providing that the low water activity of the cytosol does not 
alter the equilibrium. Nevertheless we cannot ignore the very attractive hypothesis, that the 
experimental evidences here reported are related to the regulation of the 6PGDH activity. 
An indirect evidence that the effect on the association-dissociation rate is related to other 
peculiar properties of the enzyme comes from the behaviour of the enzyme mutants. Both 
the nearly inactive enzymes (K185R and E192Q) and the nearly full active enzyme 
(C372S) display neither the effect of NADPH on the oligomerization rates nor the half-site 
reactivity in the ternary complex. This means that perturbations of the conformational 
changes affecting the rate of oligomerization also affect the correct formation of the 
ternary complex. 
The pentose phosphate pathway is regulated by the NADPH/NADP ratio that 
inhibits/activate the glucose-6-phosphate dehydrogenase (G6PD) leading to the formation 
of 6PG. Also the 6-phosphogluconate dehydrogenase is strongly inhibited by NADPH, and 
its maximal activity in T. brucei is nearly equal to the activity of G6PD [80]. It has been 
reported that in cancer cells, where the glycolysis is strongly enhanced, depletion of G6PD 
affects the cell viability only under oxidative stress [81], while depletion of 6PGDH and 
accumulation of 6PG, affect the cell viability also in the absence of oxidative stress [82]. In  
T. brucei bloodstream form, where the glycolysis is the only energy source, it is mandatory 
to ensure an efficient clearing of the 6PG [78]. All the previously reported 6PG effects  
promote an increased catalytic efficiency of the enzyme, and the present observation of the 
6PG effect on the enzyme association/dissociation rate suggests that, also in the present 
case, we deal with a yet unclear mechanism to surmount the NADPH inhibition. 
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RESULTS, DISCUSSION 
AND CONCLUSION 
 
 Part II. Functional studies. Results and Discussion 
The pH dependence of V and V/K for the T. brucei 6PGDH, have been already determined 
[85] Both V and V/K show a bell-shaped curve. Also the pKm for 6PG and NADP against 
pH have a bell shape. As shown in Figure 26, two pKa, 7.17 and 9.65, can be observed in 
the graph with pKm for 6PG. The group with pKa 7.17 is likely one of the groups that 
release H
+
 upon binding of 6PG, always it has been thought the lysine 185 pKa, that must 
be non-protonated in the enzyme substrate complex while the pKa 9.65 is likely that of the 
glutamate 192 in the enzyme-substrate complex, that must be protonated in the enzyme 
substrate complex. 
 
 
            Figure 26: pKm  dependence from pH for 6PG  in T. brucei 6PGDH [85] 
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a) Effect of mutation on the enzyme activity 
 
a.1) E192Q 
This mutant show a strongly decreased enzymatic activity, the specific activity is 0.028 
µmol min
-1
mg
-1
, against a value of 20 µmol min
-1
 mg
-1
 for the WT. The pH dependence of 
Vmax is, within the experimental error, a flat line similar to that observed in the E190Q 
mutant of the sheep liver enzyme. 28   
 
 
a.2) K185H  
This mutant presents a peculiar biphasic kinetics, with an initial faster phase producing few 
equivalents of product, followed by a second slow, steady state phase. The rate of the fast 
phase is about three orders of magnitude lower than WT (0.013 mol min-1 mg-1), while 
the rate of the steady-state phase is four orders of magnitude lower than WT (Figure 27). 
The specific activity value for the initial phase is approximate, due to the non-linear 
kinetics, and other classical kinetic parameters could not be determined, for the same 
reason. Analysis of the burst kinetics shows that the initial rate is approximately 
proportional to the enzyme concentrations, and its amplitude depends on the concentrations 
of the substrates. The rate of the slow phase loses dependence on the enzyme 
concentration, but it depends only from the amplitude of the fast phase. This suggests that 
during the fast phase there is an approach to the equilibrium of the enzyme-catalyzed 
reaction, with the formation of an unknown intermediate. This intermediate decays non-
enzymatically during the slow phase, causing a further progress of the enzymatic reaction. 
The burst-phase amplitude, extrapolated to time zero, measured at different concentrations 
of the substrates and at different pH, allowed the equilibrium constant between reagents 
and products to be calculated. The calculated value, taking into account the hydrogen ion 
concentration, was 6.3 10
-12
 M, close to 1.84 10
-11
 M, the Keq for the dehydrogenation of 2-
deoxy 6-phosphogluconate to 3-keto 6-phosphogluconate 30 suggesting that the 
intermediate is the 3-keto 6-phosphogluconate. The low amount and the low stability of the 
intermediate precluded an unambiguous identification. 
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Despite the reaction product has not been identified, the reaction seem to be arrested after 
the dehydrogenation. In the next step, the decarboxylation of the 3-keto-6-
phosphogluconate, lysine 185 should give an H
+
 to the 3-keto oxygen to give the dienol 
intermediate. The pKa of the histidine should be too low to be protonated, thus the 
decarboxylation is impaired. At the same time while the protonated lysine contributes to 
the strong binding of the keto intermediate, the non-protonated histidine could allow the 
release of the 3-keto-6-phosphogluconate in the medium. 
 
 
    Figure. 27: Kinetics of the mutant K185H. 
 
a.3) H188L  
This mutant shows only a moderate decrease of the enzymatic activity (1.31 mol min-1 
mg
-1
 against 20 for the WT). The V/KNADP is pH dependent showing two pKa, 6.95 and 9.6, 
very close to the pKa observed for the WT enzyme (not shown). 
 
 
b) Cysteine reactivity 
Not only kinetic studies show that 6PG binding potently effects the enzyme [74] but also 
structural studies like reactivity toward chemicals, denaturating agents and proteolysis 
evidence that in the presence of the substrate there is a strong reactivity reduction, 
consistent with an induced conformational change of the enzyme 31. DTNB titration 
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allows to measure cysteine reactivity, in the T. brucei WT three cysteines for subunit are 
fast titrated at pH 7.5, but in presence of 6PG one cysteine alone is titrated in more than 10 
minutes (Figure. 28). Also in the mutant E192Q and K185H there is a reduction of 
reactivity in the presence of 6PG (data not shown). Instead in the H188L mutant the 
cysteine reactivity is still high also in the presence of 6PG (Figure 28). 
 
 
   Figure 28: The cysteines reactivity in absence and in presence 
    of 6PG for WT and H188L mutant. 
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c) 6PG binding to 6PGDH 
The binding of 6PG to 6PGDH has been studied by ITC in the WT enzyme and in three 
mutants: E192Q, K185H and H188L. While E192 and K185 are the active site residues 
involved in catalysis, H188 is a conserved residue at 4-5 Å from  E192. 
The proton uptake/release accompanying the binding has been measured at three different 
pH, titrating the enzyme in different buffers. The data are summarized in Table 12.  
 
 
 
Table 12: Intrinsic Kd, pKa and number of proton exchanged at the 6PG binding. 
               *The sign – indicates proton release, values refer to enzyme subunit, nd, not detected. 
 
c.1) The binding of 6PG to 6PGDH WT  
The binding of 6PG to 6PGDH shows a pH dependence indicating the requirement of a 
protonated group with pKa 7.07 (Figure 29). On the basis of the observed Kd, no proton 
release is expected, while a proton uptake is expected at pH higher than 7.0. Instead at all 
pH tested the binding is accompanied by a release of hydrogen ions. The pKa of 6PG is 6.3 
83 therefore if only the ionized form of the substrate binds to the enzyme, at pH 6.5 the 
proton release can be totally accounted for by the ionization of 6PG. The pKa decrease at 
pH lower than 7 suggests that unprotonated 6PG binds to the enzyme. However at pH 
>7.0, other group(s) must be involved to balance the observed protons release. At least 1.5 
H
+
 are required to account for the proton uptake of the group with pKa 7.07 and the release 
of H
+
 observed experimentally. A scheme with three residues involved is shown in Figure 
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30, where that with the pK of 7.07 binding a proton released by a second residue, while a 
third residue releases hydrogen ions in the buffer. 
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                    Figure: 29:  pH dependence for 6PG apparent pKd 
 
 
 
 
Figure 30:  Scheme with three residues involved in the change of the protonation state of the 
 enzyme at the substrate binding 
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c.2) The binding of 6PG to E192Q  mutant 
This mutant shows a Kd pH independent (data not shown), and one order of magnitude 
higher than that of the WT enzyme. This suggests that the group with pKa 7.07 observed in 
the WT enzyme is absent in the mutant. Accordingly to the proposed mechanism of 
6PGDH, the glutamate 192 should become protonated in the enzyme-substrate complex. 
We measured the proton uptake/release of the E192Q mutant, where the mutated residue 
cannot accept H
+
. At pH 6.5 the behaviour of the mutant is identical (within the 
experimental error) to the WT. However at higher pH the binding is accompanied by a 
large proton release, reaching about 1.8 H
+
 released at pH 8.5. The excess of proton 
release, i.e the difference between WT and E192Q enzymes, is coherent with the lack of a 
protonable group with pKa 7.0. The data evidence the lack of a proton-accepting group, 
and suggest that the group that must be protonated for the binding of 6PG is E192.  
The 6PG binding enthalpy increase, at higher pH correlates with augmentation in the 
number of H
+
 released (Table 13). As already shown 6PG binding is mainly entropy 
driven, with entropy gain resulting from the desolvation of the phosphate [19] . 
 
 
 
 
                Table 13:  Buffer-independent enthalpy change and number of  hydrogen ions exchanged at    
 different pH in the mutant E192Q at  the 6PG binding. 
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c.3) The binding of 6PG to K185H mutant 
Lysine 185 is thought the residue that accepts the hydrogen ion from the 3 OH of the 6PG 
during the first step of the catalysis and should be non protonated in the enzyme substrate 
complex. Thus this residue is expected to be one of the two groups that release H
+
 upon 
substrate binding. The Kd of the K185H mutant is pH dependent with an apparent pKa of 
7.4 (table 12), meaning that the group that must be protonated in the enzyme-substrate 
complex is still present. Mutation of K with H, whose natural pKa is about 3.5 units lower 
than the pKa of the lysine, should cause the disappearance of an hydrogen donating group 
from the proton balance. In fact the mutant K185H shows, at pH 7.5 and 8.5, an uptake of 
H
+
, while at pH 6.5, where also the histidine is protonated, the mutant behaves like the 
WT. The difference in proton balance between WT and K185H enzymes, is coherent with 
the lack of a H
+
 releasing group with pKa 7.4. The data suggest that 6PG binds to the 
protonated form of the enzyme (into both the residues K185 and E192) and, upon binding, 
K185 releases its hydrogen ion.  
 
 
c.4) The binding of 6PG to H188L mutant 
H188 is conserved in all the 6PGDHs and is buried at 4-5 Å from E192. This residue was 
mutated to L, to keep a bulky side chain. The Kd of the H188L is one order of magnitude 
higher than that of the WT enzyme, and it is pH dependent with an apparent pKa of 7.2, 
meaning that the group that must be protonated to bind the substrate is still present. The 
proton release was very similar to the WT enzyme with only pH 8.5 showing significant 
differences. From the number of proton exchanged upon the binding it is possible to 
recover a change in pKa of the residues involved (see methods). The difference in proton 
release between WT and H188L suggests that the mutant enzyme lacks of a group whose 
pKa drops from >10.0 to 8.65 upon binding of the substrate. These pKa are hardly attributed 
to a buried histidine, and probably reflect small conformational changes accompanying the 
binding of the substrate. 
 
The current mechanism hypothesized for 6PGDH requires that two essential groups, K185 
and E192, invert its ionization state upon binding of the substrate, K185 becoming 
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unprotonated while E192 protonated. Our results give experimental support to the 
proposed mechanism, in fact the lack of the proton-accepting group, E192, causes a greater 
H
+
 release, while the lack of the proton releasing group, K185, causes an H
+
 uptake. 
Starting from these observations it is possible to describe the ionization state of the free 
and substrate bound enzyme.  
6PGDH has a rapid equilibrium random kinetic mechanism [86], and with 6PG maintained 
at a saturating concentration, the kinetic mechanism can be described schematically as 
shown in Figure 31. 
 
 
         Figure 31: Kinetic mechanism of 6PGDH 
 
 
The pKa of the two residues in the enzyme-substrate complex  can be obtained by the 
pH dependence of V/KNADP. In fact V/K is 
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  Equation 15. V/K equation 
 
 
In this equation ki and ki+1 refer to the conversion of the same intermediate specie in the 
forward and reverse directions, and this, accordingly to the mechanism (Figure 31 and 
equation 15), requires the same ionization state for the catalytic residues involved in the 
reaction. Thus a change in the ionization of catalytic residues induced by pH should affect 
at the same extent both rate constants. The only rate that can be still dependent on the pH is 
[E]k1, where [E] is the fraction of correctly protonated enzyme, i.e. the fraction of 
k
5 
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catalytically competent enzyme. In the case of V/KNADP the catalytically competent 
enzyme is the enzyme-6PG complex, and shows two pKa,  7.17 and 9.65. The pKa 7.17 
could be assigned to the K185, that must be non-protonated in the enzyme substrate 
complex, while the pKa 9.67 could be assigned to the E192, that must be protonated in the 
enzyme substrate complex.  
 
In the free enzyme the pH dependence of the dissociation constant of T. brucei 6PGDH for 
6PG evidences the requirement of a protonated group with pKa 7.07. Despite this pKa 
appears anomalous for a glutamate, it can be assigned to the glutamate192, in fact mutation 
of this residue with glutamine causes the disappearance of the pH dependence of the Kd. 
Furthermore the difference in H
+
 release between WT and E192Q mutant enzymes fit 
fairly well with the disappearance of a group whose pKa changes from 7.07 to 9.67, upon 
substrate binding. The requirement of a protonated form for the glutamate 192 can be 
easily predicted by its proximity with the carboxylate group of the substrate. The crystal 
structure of 6PGD-6PG complex is available for the enzymes from sheep liver (1PGD), E. 
coli (2ZYA) and Geobacillus stearothermophilus (2w8z). Despite small differences in 
substrate conformations, the glutamate is in all cases less that 4.0 Å from the carboxylate 
of 6PG. 
 
The pKa of K185 in the free enzyme can be evaluated from the proton uptake of the K185H 
mutant. In fact the differences in H
+
 release/uptake between WT and K185H mutant 
enzymes should correspond to the H
+
 released by K185. The data are consistent with a 
group changing its pKa from 9.3 to 7.17, therefore a pKa 9.3 can be estimated for K185 in 
the free enzyme. 
 
At pH 6.5 and pH 8.5, the proton balance evidences that other residues are involved in the 
binding. At pH 6.5 the excess of H
+
 can be assigned to the dissociation of 6PG, in fact both 
WT and mutant enzymes show a very similar proton release that corresponds to the 
ionization of 6PG (pKa 6.3). At pH 8.5 it is likely that the excess of H
+
 release does not 
arise from a single group, but is the result of several small ionization changes induced by 
the conformational changes accompanying the substrate binding. Nevertheless all these 
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changes can be collectively described with good approximation by a single group. Thus a 
minimal model for the ionization changes induced by the substrate binding should account 
for three groups: the glutamate 192, whose pKa increases from 7.07 to 9.67, the lysine 185 
whose pKa decreases fro 9.3 to 7.17, and a third group whose pKa is downshifted. 
 
The differences in H
+
 release between WT and H188L mutant enzymes can be described 
with a group changing its pKa from 10.5 to 8.65. These pKa values are hardly attributable to 
the histidine 188, instead it is likely that arise from different small ionization changes due 
to the conformational changes induced by the substrate. In fact the more interesting 
property of this mutant is the absence of the effect of 6PG on the reactivity of thiol groups. 
In the wt enzyme the binding of 6PG suppress the reactivity of all cysteine residues, and 
this can be explained only by a conformational effect. K185H and E192Q mutants show, 
with few differences, the same 6PG effect on the reactivity of the cysteine residues, but in 
the H188L mutant the presence of 6PG does not changes significantly the reactivity of 
cysteine residues. For this reason we suggest that the differences in H
+
 release between 
WT and H188L mutant are due the conformational changes induced by substrate, and that 
all ionization changes can be collectively described as a single group changing its pKa. 
 
In conclusion the H
+
 release/uptake of 6PGDH WT and its mutants can be described with 
good approximation taking into account three enzyme groups and 6PG (Figure 32): lysine 
185 (lacking in the K185H mutant) with pKa changing from 9.3 to 7.17; glutamate 192 
(lacking in the E192Q mutant) with pKa changing from 7.07 to 9.67; a group representing 
at least part of the conformational changes (lacking in the H188L mutant) with pKa 
changing from 10.5 to 8.65; 6PG with pKa 6.3 that binds only in the ionized form. 
 
With a reasonable model available for the ionization changes occurring with the formation 
of the enzyme-substrate complex, it is also possible to assign the ionization enthalpies to 
the single residues by comparing the binding enthalpies of the 6PG to the WT enzyme with 
the binding enthalpies of the mutants. 
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The difference in the binding enthalpy between WT and E192Q mutant, together with the 
difference in proton release, gives the enthalpy contribution of the protonation of the 
glutamate 192. In the same way the difference in the binding enthalpy between WT and 
K185H mutant gives the contribution of the protonation of the lysine 185 and the 
difference in the binding enthalpy between WT and H188L mutant gives the contribution 
of the protonation changes attributed to the conformational changes. With the only 
exception of E192Q at pH 8.5, the data at different pH fits quite well giving for the E192 a 
H -3.5± 0.9 kcal/mole, for K185 H -9.83 ± 1.6 kcal/mole, and for conformational 
changes H 7.97 ± 0.95 kcal/mole. From these values, and from the model for the change 
in the ionization state previously described, the intrinsic binding enthalpy can be 
calculated, i.e. the binding enthalpy for the correctly protonated substrate to the correctly 
protonated enzyme. The calculated intrinsic binding enthalpy is -4.6 ± 0.23 kcal/mole, and 
this value, although it includes both experimental and fitting errors, clearly shows that a 
large part of the binding enthalpy is spent to put the enzyme in the correct protonation 
form. Accordingly to the proposed mechanism (Figure 31) at the end of the reaction the 
protonation of the enzyme-product complex is the same of that of the free enzyme, 
therefore the energy spent during the binding of the substrate will be regained during the 
catalytic cycle. 
 
       Figure 32:  Scheme for the pKa shifts for ionizable residues in the T. brucei 6PGDH 
        upon formation of the enzyme-6PG complex. S, substrate 6PG, P, enzyme, E, E192, K, K185. 
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Part II. Functional studies. Conclusion 
The model described, even if simplified, allows to describe with good approximation, the 
change in the protonation state of 6PGDH upon substrate binding. 
The main uncertainty comes from the operative need to put in one pKa change the 
ionization variations due to conformational changes, while most probably a number of 
groups are involved. 
Data show that K185 is unprotonated in the enzyme-substrate complex while E192 is 
protonated. Furthermore in the bell K6PG-pH curve the two pK of 7 and 9.5 have always 
been attributed to K185 and E192 but being so different from the natural pK of a lysine 
and glutamate it was thought that they were only apparent pK and only a small fraction of 
the enzyme was in the right protonation state, able to display the catalytic activity. Our 
results show that the pK of K185 and E192 really can move after the substrate binding to 
the values of 7 and 9.5, respectively. Thus kinetic parameters with good approximation 
correspond to the true pK of key aminoacids in catalysis. 
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